Generally, only parental education, anticipatory guidance, and modification of feeding composition, frequency, and volume are necessary for the management of uncomplicated infant GER (208,420). Overfeeding exacerbates recurrent regurgitation and should be avoided (211). In some infants with persistent regurgitation, a thickened or commercial antiregurgitation formula may help control the frequency of regurgitation (Section 4.1.1). There is no evidence that antisecretory or promotility agents improve physiologic infant regurgitation. Prone positioning is not recommended because of its association with SIDS. Because regurgitation is sometimes the sole manifestation of cow's milk protein allergy in healthy-looking infants (420,421), a 2-week trial of protein hydrolysate– or amino acid–based formula or a trial of milk-free diet for the breast-feeding mother is appropriate in infants not responding to previous management.
The infant with recurrent regurgitation and poor weight gain should not be confused with the “happy spitter” described in Section 6.1.1. Whereas the history and physical examination may be identical, poor weight gain is not typical of uncomplicated infant GER and is a crucial warning sign that alters clinical management.
Because there are no well-controlled studies evaluating diagnostic or therapeutic strategies for these infants, the following approach is based on expert opinion (Fig. 2). A feeding history should be obtained that includes an estimate of energy offered and ingested per day, an estimate of energy loss through regurgitation, a description of formula preparation and feeding schedule, an assessment of breast milk sufficiency, and a description of infant sucking and swallowing behavior. Parents should be advised not to reduce intake to the point of energy deprivation in the attempt to prevent regurgitation. If problems identified by history seem to explain the symptoms and can be addressed, close outpatient monitoring of weight gain will determine whether further evaluation is indicated.
If chronic regurgitation and inadequate weight gain persist after observation and despite adequate energy intake, evaluation for causes of failure to thrive compatible with the history is mandatory. Among possible etiologies in infancy are infections (especially urinary tract), food allergy, anatomic abnormalities, neurologic disorders, metabolic disease, and neglect or abuse (Table 4). A 2- to 4-week trial of extensively hydrolyzed or amino acid–based formula is appropriate. Depending on the results of investigations and response to dietary management, the infant should be referred to a pediatric specialist. Hospitalization for observation and testing is appropriate in some infants with persistent failure to thrive. Nasogastric or nasojejunal feeding is occasionally necessary to achieve weight gain in the infant with no other clear explanation for poor weight gain (231).
Irritability and regurgitation are nonspecific symptoms that occur in healthy infants and are associated with a wide range of physiologic and pathologic conditions. For example, exposure to environmental factors, such as tobacco smoke may result in irritability in infants (422,423). Healthy young infants fuss or cry an average of 2 hours daily. There is substantial individual variation and some healthy infants cry as much as 6 hours per day. Likewise, there is variation in parental perceptions regarding the severity and duration of crying and its importance. The amount of daily crying typically peaks at 6 weeks of age (424,425). As with fussing, sleeping patterns of healthy infants show great individual and maturational variation as do parental expectations for sleep behavior (426).
The concept that infant irritability and sleep disturbances are manifestations of GER is largely extrapolated from adult descriptions of heartburn and sleep disturbances that improve with antacid therapy (50,427–429). Although 1 study in infants showed a correlation between infant grimacing and episodes of reflux (430), multiple other studies have shown no relation between crying and GERD determined by esophageal pH testing (61,84,140,431) or the presence of esophagitis (47,84). Some small descriptive studies have evaluated pH probe studies in infants with irritability and sleep disturbance. One compared infants with normal and abnormal pH probe studies and found a slight increase in nighttime waking, delayed onset of sleep, and greater daytime sleeping in those with abnormal pH probe studies (432). Another study found no increase in sleep disturbance in infants with abnormal esophageal pH tests (431). One dual pH probe study showed slightly poorer proximal acid clearance in colicky infants, but no abnormality in other parameters (433). Recently, a study of colicky infants found abnormal pH test results only in those with excessive regurgitation or feeding difficulties (61).
There are few studies addressing the appropriate management of infants with irritability and reflux symptoms. One study showed a greater decrease in crying time in infants treated with a 1-mg/kg dose of famotidine than in infants given 0.5 mg/kg. Although the authors concluded from this study that famotidine was effective in treating infant crying, differences in age between treatment groups, absence of placebo control, and a lack of difference between the treatment group and a group withdrawn from medications cast doubt on this conclusion (293). Placebo-controlled studies have evaluated acid-suppressive therapy in irritable infants. A study of infants with irritability and normal esophageal pH tests found that combined ranitidine and cisapride treatment was not superior to placebo or counselling for persistent crying (45). A double-blind placebo-controlled trial of omeprazole in irritable infants who either had esophagitis or an RI >5% found no difference in crying between treated and placebo groups despite highly effective acid suppression in the treated group (46). A large double-blind study of 162 infants randomized to 4 weeks of placebo or lansoprazole showed an identical 54% response rate in each group, using an endpoint of >50% reduction of measures of feeding-related symptoms (crying, irritability, arching) and other parameters of the I-GERQ questionnaire (9). Furthermore, this study showed a small but significant increase in the numbers of infants that experienced lower respiratory symptoms during the treatment trial.
The available evidence does not support an empiric trial of acid suppression in infants with unexplained crying, irritability, or sleep disturbance. A symptom diary (61,434) or hospital observation (45,435) may be useful to confirm the history, which is subjective to observation bias.
Disorders other than GERD that are likely to cause irritability include cow's milk protein allergy (142,436), infections (especially of the urinary tract), constipation, respiratory disorders, congenital or acquired neurologic abnormalities (437), metabolic disease, surgical emergencies (eg, intermittent volvulus, ovarian torsion), cardiac disease, corneal abrasion, bone fractures, hair tourniquet syndrome, tobacco smoke exposure, hunger, abuse, or neglect (438,439). Allergy to cow's milk protein or other formula intolerance may cause infant irritability, distress, and vomiting indistinguishable from GER. In 1 controlled study, an empiric trial of formula made with partially hydrolyzed whey proteins, prebiotic oligosaccharides, and a high β-palmitic acid content significantly decreased colic (440). Data on the efficacy of extensively hydrolyzed formulae in infants with unexplained crying and/or distressed behavior are limited (441,442). An empiric 2- to 4-week trial of an extensively hydrolyzed formula (1 that has been validated as being tolerated by at least 90% of infants with cow's milk protein allergy with 95% confidence) or amino acid–based formula may be indicated in irritable infants after diagnostic evaluations have been performed for other conditions causing irritability. Reflux is an uncommon cause of irritability or unexplained crying in otherwise healthy infants. However, if irritability persists with no explanation other than suspected GERD, expert opinion suggests the following options. The practitioner may continue anticipatory guidance and training of parents in the management of such infants with the expectation of improvement with time. Additional investigations to ascertain the relation between reflux episodes and symptoms or to diagnose reflux or other causes of esophagitis may be indicated (pH monitoring ± impedance monitoring, endoscopy). A time-limited (2-week) trial of antisecretory therapy may be considered, but there is potential risk of adverse effects, and clinical improvement following empiric therapy may be due to spontaneous symptom resolution or a placebo response. The risk/benefit ratio of these approaches is not clear.
Physiologic regurgitation, episodic vomiting, or regurgitation followed by swallowing of refluxate in the mouth are frequent in infants. Whether of new onset or persisting from infancy, these symptoms are less common in children older than 18 months of age. Although these symptoms are not unique to GERD, evaluation to diagnose possible GERD and to rule out alternative diagnosis is recommended based on expert opinion. Testing may include upper GI endoscopy, and/or esophageal pH/MII, and/or barium upper GI series (Table 4).
Heartburn or substernal burning pain is a symptom of GERD with or without esophagitis (443). Recent consensus statements suggest that typical heartburn is a reliable indicator for GERD in adolescents and adults if it is the dominant symptom (13,50). One study in adults found that dominant heartburn had a positive predictive value of 81% for GERD determined by pH study (444), but other studies have not confirmed this close association between history and test results (378). Esophageal pH probe results are normal in one third of adults with chronic heartburn, even those whose heartburn is reproduced by esophageal acid perfusion and those who respond favorably to antacids. Some adults with heartburn and normal pH studies have endoscopically proven esophagitis (445). In older children and adolescents the description and localization of heartburn pain is probably reliable. In young children, however, symptom descriptions and localization may be unreliable (56–60,446).
No randomized placebo-controlled studies evaluate lifestyle changes or pharmacologic therapy of heartburn in children or adolescents. Case series have shown that PPI therapy relieves heartburn symptoms in adolescents (55,64,447). Expert opinion suggests using a management approach to heartburn in older children and adolescents similar to that used in adults (Fig. 3). Other causes of heartburn-like chest pain including cardiac, respiratory, musculoskeletal, medication-induced, or infectious etiologies should be considered. If GERD is suspected as the most likely cause of symptoms, lifestyle changes, avoidance of precipitating factors, and a 2- to 4-week trial of PPI are recommended (446,448–450). If there is no improvement following empiric therapy, the older child or adolescent should be referred to a pediatric gastroenterologist for diagnostic evaluation. If improvement follows PPI therapy and lifestyle changes, treatment can be continued for 2 to 3 months. In some patients, abrupt discontinuation of treatment may result in acid rebound that precipitates symptoms; therefore, it is recommended that antisecretory therapy be weaned slowly (451,452). If symptoms recur when therapy is weaned or discontinued, upper endoscopy may be helpful to determine the presence and severity of esophagitis and differentiate reflux-related esophagitis from nonreflux pathologies such as infection or EoE that may present with heartburn (40,453) Because chronic heartburn can have a substantial negative impact on quality of life, long-term therapy with PPIs may be required, even in the absence of esophagitis (454,455). Extrapolation from adult data suggests that in older children and adolescents, on-demand or intermittent therapy with antacids, H2RA, or PPIs may be used for occasional symptoms of heartburn (302,455,456).
In open-label studies of children with erosive esophagitis, PPIs produced healing in 78% to 95% with 8 weeks of therapy and in 94% to 100% with 12 weeks of therapy. Symptoms improved in 70% to 80% of the group treated for 12 weeks (130,312,447). Most patients in these studies had lower grades of erosive esophagitis, and the studies did not include patients with underlying conditions such as NI, repaired tracheoesophageal fistula, chronic lung disease, or HH. PPIs have been shown to heal higher grades of esophagitis (grades 3–4) in children with these underlying conditions, even in some when esophagitis had been refractory to treatment with H2RAs, prokinetic agents, and even antireflux surgery (28,29,131). However, in these selected cases resistant to standard management, high per-kilogram dose and long duration of therapy (up to 6 months) may be required for healing and symptom control (28,29,131).
In uncontrolled studies of children with erosive and nonerosive disease treated with PPIs, 70% experienced relief of “typical symptoms of GERD,” that is, heartburn (312,447). A significant percent of patients remained symptomatic, albeit at lower intensity. Suboptimal symptom relief may be due to large per-kilogram dosing variation. Studies in adults have shown generally poorer therapeutic response to PPI in patients with NERD compared with patients with erosive esophagitis (457,458).
With regard to maintenance therapy, in a prospective study of children whose erosive esophagitis had healed following 3 months of omeprazole therapy, only half maintained the remission of symptoms and endoscopic disease in a maintenance phase during which they received half the healing dose of PPI (316). In another study, patients whose erosive esophagitis healed after 3 months' omeprazole treatment (1.4 mg · kg−1 · day−1) underwent double-blind randomization into 3 groups, receiving either maintenance therapy with omeprazole at half the healing dose, ranitidine, or placebo for 6 months (130). In all 3 groups, few patients had a relapse of symptoms or of endoscopic esophagitis during or after maintenance therapy. There were important differences between these 2 studies. Specifically, in the first study, the mean grade of esophagitis was higher, and 41% of patients had an underlying disorder predisposing to GERD. In a retrospective study of 166 children with erosive esophagitis unable to withdraw from PPIs for up to 11 years (median 3.5 years), 79% had at least 1 underlying condition predisposing them to GERD and 39% had HH (28). Thus, patients with lower grades of erosive esophagitis and without an underlying high-risk condition may not require long-term PPI therapy after initial effective treatment. In a recent study of adults with long-term PPI use, 27% were able to discontinue drug without relapse (452).
PPIs are recommended as initial therapy in children with erosive esophagitis. Initial treatment for 3 months is advised. If adequate control of symptoms is not achieved within 4 weeks, the dose of PPI can be increased. Patients who require higher PPI dose to control symptoms and produce healing are those with conditions that predispose to severe-chronic GERD and those with higher grades of esophagitis or BE. In most cases, efficacy of therapy can be monitored by extent of symptom relief without routine endoscopic follow-up. Endoscopic monitoring of treatment efficacy may be useful in patients whose presenting signs and symptoms are atypical, who have persistent symptoms while taking adequate acid-suppressive drugs, or who had higher grades of esophagitis or esophageal stricture at presentation (see also Section 5.2.2). Follow-up endoscopy is not routinely indicated in patients with nonerosive disease, particularly if they are asymptomatic on medication.
Most patients require only 1 daily dose of PPI to obtain symptomatic relief and heal esophagitis (29,131,447,459). The optimum dosage regimen is to administer a once-daily dose 15 to 30 minutes before the first meal of the day. It is not necessary to make patients achlorhydric to relieve symptoms or heal esophagitis, and, in light of the data on infectious and other complications of acid suppression by H2RAs or PPIs, it is probably not desirable to do so.
The prevalence of BE is much lower in children than adults, but it does occur in children with severe-chronic GERD. In 1 group of children with severe-chronic GERD, columnar metaplasia was present in 5% and columnar metaplasia with goblet-cell metaplasia was present in another 5% (28). Accuracy of diagnosis has important implications for longevity and surveillance. The diagnosis of BE is both overlooked and overcalled in children (28,134). Therefore, the primary task of the gastroenterologist is accuracy of diagnosis, especially in light of the proposed new criteria for the diagnosis of BE in children and adults (13,50). If esophagogastric landmarks are obscured by bleeding and exudate, a course of high-dose PPI for at least 12 weeks before making a diagnosis is advised to allow for better visualization of anatomic landmarks and to remove the histologic changes of chronic inflammation that may confuse the diagnosis. After PPI therapy, multiple biopsies should be taken to characterize the type of BE and to rule out dysplasia (134,148).
Dysphagia, or difficulty in swallowing, occurs in association with oral and esophageal anatomic abnormalities, neurologic and motor disorders, oral and esophageal inflammatory diseases, and psychologic stressors or disorders. GERD is commonly cited as a cause of dysphagia or odynophagia, and although it may be causal in some patients, there are no pediatric data demonstrating this relation, nor has symptom improvement in infants and children been demonstrated with antireflux therapy. In a population-based Australian study, 16% of healthy adults reported having “dysphagia ever” (462). In this study, dysphagia correlated with anxiety and depression but also with GERD (odds ratio 2.96) (462). Another study found dysphagia in 11% of healthy adults and 28% of adults with GERD symptoms (463). In a meta-analysis of 11,945 adults with erosive esophagitis, 37% had dysphagia (464). However, in young adults presenting with dysphagia, radiographic evaluation demonstrated conditions other than GERD in 70% that were more likely causes of the symptoms (465). Dysphagia is a prominent symptom in up to 80% of adults and children with EoE (93,450,466).
Odynophagia, or pain caused by swallowing, must be distinguished from heartburn (substernal pain caused by esophageal acid exposure) and dysphagia. Although odynophagia may be a symptom of peptic esophagitis, it is more often associated with other conditions such as oropharyngeal inflammation, esophageal ulcer, EoE, infectious esophagitis (eg, infection with herpes simplex, candida, or cytomegalovirus), and esophageal motor disorders. A patient with odynophagia may in time develop behaviors around eating that resemble dysphagia. There are no pediatric studies on the relation between GERD and odynophagia.
Patients often find it difficult to distinguish between dysphagia and odynophagia. In the majority of patients with dysphagia, the dysphagia is not caused or related to reflux disease. The present literature indicates that dysphagia is frequent among patients with EoE. In those relatively uncommon patients in whom GERD causes dysphagia, esophagitis is often present. Expert opinion suggests that odynophagia may be associated with peptic esophagitis and esophagitis of other causes.
Feeding refusal and feeding difficulty are terms used mainly to describe the following infant symptoms: refusal to eat, uncoordinated sucking and swallowing, gagging, vomiting, and irritability during feeding. A relation between GER or GERD and feeding refusal has not been established. Although older case series suggest that reflux disease caused infant feeding difficulty, no prospective studies have proven causation and none have shown resolution with GERD therapy (467). One retrospective study found a higher incidence of poor intake, decreased feeding readiness, and food refusal in infants with abnormal pH probe tests than in normal case controls (468). Another study found no association between GERD diagnosed by pH probe and feeding difficulty, except in infants who also had excessive regurgitation (61). A double-blind placebo-controlled trial showed no improvement in feeding difficulties following lansoprazole therapy compared with placebo in infants with suspected GERD (9). A recent study found that anorexia or feeding refusal was occasionally a symptom of erosive esophagitis in children 1 to 5 years of age (40).
An upper GI contrast study is useful but not required for the infant with feeding refusal or difficulty or the older child reporting dysphagia. Its major use is to identify a non-GERD disorder such as achalasia or foreign body or to identify esophageal narrowing from a stricture. The upper GI contrast study or a more focused videofluoroscopic swallowing study that evaluates the mechanisms of feeding and swallowing may be helpful to identify nonesophageal causes of feeding difficulties, especially in infants and younger children. In children and adolescents who report dysphagia or odynophagia in combination with esophageal symptoms, endoscopy with biopsy is useful to distinguish among causes of esophagitis.
There is no evidence that supports a causal relation between infant feeding difficulties and GER or GERD. In the infant with feeding refusal, acid suppression without earlier diagnostic evaluation is not recommended. Direct observation focused on neurologic, behavioral, metabolic, and infectious disease is essential for the evaluation and diagnosis of this symptom complex (469). In the older child or adolescent empiric antisecretory therapy is only recommended if there are additional symptoms or findings suggesting GERD.
The literature on the relation between apnea, respiratory pauses, apparent life-threatening events (ALTEs) or SIDS, and reflux is conflicting, in large part because of the different criteria used to define breath stoppage, the various methods used to measure reflux and respiratory pauses, and the different populations studied.
A recent study combining data from simultaneous esophageal pH/MII and cardiorespiratory monitoring in infants showed a temporal association between 30% of the nonpathologic, short episodes of central apnea and reflux (115). These findings cannot be extrapolated to pathologic infant apnea and may represent a normal protective cessation of breathing during regurgitation. Recent studies using combined pH/MII have generally detected little relation between apneic spells and reflux episodes (470,471). Some studies have found a relation between long episodes of apnea (>30 seconds) and acid reflux in premature infants (472). In 1 older study, short apnea or bradycardia spells were tightly tied to spells of vomiting or regurgitation, whereas the majority of prolonged apnea spells (>20 seconds) were not (473). In highly selected cases, reflux is clearly associated with pathological, central, and obstructive apnea (241). None of these studies has conclusively shown a cause and effect relation between reflux and pathologic apnea.
ALTEs are frightening episodes in infants characterized by a combination of apnea, color change (cyanosis, pallor, and plethora), abnormal muscle tone (limpness and stiffness), choking, and gagging that require intervention by the observer (474). The identification of a behavior as ALTE is observer dependent (475). The first event usually occurs at 1 to 2 months of age and rarely after 8 months. ALTEs may recur (476,477), and infants with an ALTE are at slightly increased risk for subsequent sudden death (477–482). ALTEs may be associated with infection, child abuse, upper airway obstruction, cardiac, respiratory, metabolic, and neurologic disorders. ALTEs associated with reflux may not be pathologic; some may be an exaggeration of normal protective reflexes that inhibit breathing while the infant retches or while the pharynx is filled with gastric contents.
In older studies, patients with ALTEs had a 60% to 70% prevalence of recurrent regurgitation or emesis (475,477), and abnormal esophageal pH tests were documented in 40% to 80% of patients with ALTEs (483,484). Case reports and series described ALTEs triggered by overt regurgitation into the oropharynx, by aspiration of refluxed gastric contents, and by reflux induced by positional change after feedings (485–488). In selected patients with ALTE, acid perfusion of the esophagus induces obstructive apnea (485) or oxygen desaturation (483), suggesting that 1 mechanism for ALTE is acid stimulation of laryngeal, pharyngeal, or esophageal chemoreceptors with subsequent laryngospasm. In selected infants, a clear temporal relation between apnea and ALTE can be demonstrated. However, large case series have not shown a consistent statistical relation between GER and pathologic apnea or ALTEs (489,490). Larger studies using combined esophageal pH/MII may clarify the extent of these temporal relations.
Poor quality of sleep characterized by irregular breathing patterns is associated with reflux (484,489–496). Although several studies have reported an occasional correlation of GER with short mixed central apneas (5–15 seconds) (492,493,495), all of the patients also had episodes of apnea unrelated to episodes of GER, suggesting a primary impairment in the regulation of respiration.
At present there is no evidence that the characteristics of the ALTE or the polysomnographic record can predict which infants with ALTE are at risk for future life-threatening episodes or sudden death. Although rare, SIDS has been reported to occur in patients with a previous ALTE and documented GER (241,491,497). In none of these patients was a correlation between esophageal acidification and a cardiopulmonary event ever recorded.
The available evidence suggests that in the vast majority of infants, GER is not related to pathologic apnea or to ALTE, although a clear temporal relation based on history, observation or testing occurs in individual infants. Impedance/pH recording in combination with polysomnographic recording is recommended to demonstrate this relation in these infants.
Medical therapy of ALTEs suspected of being GER-related has not been adequately studied. Approaches that decrease the frequency of regurgitation and the volume of reflux such as thickened feeding may theoretically be beneficial. Pharmacotherapy has not been shown to be effective. The occurrence of ALTEs diminishes significantly with age and without therapy in most cases, suggesting that no antireflux therapy is needed. The ALTEs most likely to improve with antireflux therapy are those obviously associated with vomiting or regurgitation, those that occur in the awake infant after feeding, and those characterized by obstructive apnea. Because medical therapy has not been shown to be effective, surgery may be a reasonable approach in the rare infant in whom ALTEs are truly life threatening and are shown to be clearly related to GER.
In some exceptional situations, prone sleeping (with cardiorespiratory monitoring) may be recommended because of a major risk of apnea or aspiration caused by refluxed material.
An etiologic role for reflux in reactive airways disease (asthma) has not been established, although animal and human studies have suggested that reflux may exacerbate existing asthma. Proposed mechanisms by which reflux aggravates asthma are direct production of airway inflammation by aspirated gastric contents, airway hyperresponsiveness triggered by lower airway aspiration of minute amounts of acid, vagally mediated bronchial or laryngeal spasm, and neurally mediated inflammation (498–501). Esophageal acidification in healthy adults has minimal effect on pulmonary function (498); however, esophageal acidification in asthmatic patients can produce airway hyperresponsiveness and airflow obstruction (502).
Few studies have evaluated the impact of asthma on the severity of GERD. Chronic hyperinflation caused by asthma can flatten the diaphragms, alter crural function, and displace the lower esophageal sphincter into the negative atmosphere of the chest, effectively reducing resting LES pressure and causing disappearance of the acute esophagogastric angle of His. Lung hyperinflation and airflow obstruction may produce increased negative intrathoracic pressure, effectively increasing the pressure gradient across the diaphragm and promoting reflux. Although theophylline and β-receptor agonists cause a reduction of resting LES pressure, these drugs have not been linked to the development of GERD in treated asthmatics (503). Oral corticosteroids promote reflux in adults, but the mechanism is unclear (504).
Many studies have demonstrated an association between asthma and measurements of reflux by pH probe or pH/MII. These studies have shown that 60% to 80% of children with asthma have abnormal pH or pH/MII recordings (505). A study of 77 children 3 to 14 years old with difficult-to-control asthma found that 66% had abnormal RI on pH testing (90). In a study of 84 otherwise healthy infants with daily wheezing, 64% had abnormal 24-hour pH studies, and 44% of these had no overt symptoms of GERD (506). Nocturnal wheezing appears particularly related to GERD. One study used combined esophageal pH/MII monitoring and demonstrated a tighter association between reflux episodes and respiratory symptoms than pH monitoring alone (507), but no studies to date have shown that pH/MII studies are useful in identifying those patients whose asthma may respond to antireflux therapy.
One study found omeprazole treatment to be ineffective in improving asthma symptoms, quality of life, lung function, or use of β2 agonists in children with asthma and GERD (508). High-dose prolonged PPI therapy in adult asthmatics has shown minimal or no efficacy. In 1 large double-blind placebo-controlled study of esomeprazole in adult asthmatics, no improvement occurred in morning peak expiratory flow, but posthoc analysis indicated mild improvements in FEV1 among patients with nocturnal asthma symptoms (509). However, patients with known erosive esophagitis or moderate-to-severe GERD symptoms were excluded. Another study showed a 4% decrease in the number of asthma exacerbations and a 14% decrease in the use of oral corticosteroids in adult patients with moderate-to-severe asthma and heartburn treated with lanzoprazole for 24 weeks but no improvement in symptoms, pulmonary functions, or albuterol use (510). One uncontrolled study in children found that children with persistent moderate asthma and reflux who received antireflux treatment including PPI used significantly less medication to control their asthma (511). Another double-blind placebo-controlled study showed no reduction in wheezing among infants treated with lansoprazole versus placebo for 4 weeks, although wheezing was a secondary endpoint and not the primary focus of the study (9). A controlled trial in adults with reflux and asthma evaluated asthma outcomes after 2 years of continuous ranitidine therapy versus antireflux surgery; surgery led to a larger reduction in symptoms and improved overall clinical status, but neither therapy had a clinically meaningful impact on pulmonary function or pulmonary medication use (512). Some uncontrolled case series using nonobjective parameters have shown a dramatic improvement in asthma symptoms in children after antireflux surgery (95).
Although adult studies show only limited, if any, benefit from PPI or surgical therapy, it is possible that selected patients with heartburn, nocturnal asthma, or steroid-dependent, difficult-to-control asthma may derive some benefit. Symptom reporting is less reliable in infants and children than in adults. Therefore, a reasonable approach to evaluation of pediatric patients in whom GERD is suspected of being a contributing or aggravating factor causing wheezing or asthma is shown in Fig. 4. Other causes of wheezing should be ruled out. There is no strong evidence to support empiric PPI therapy in unselected pediatric patients with wheezing or asthma. Finding abnormal esophageal pH exposure by esophageal pH monitoring, with or without impedance, before considering a trial of long-term PPI therapy or surgery may be useful, although the predictive value of these studies for this purpose has not been established. The relative efficacy of medical versus surgical therapy for GERD in children with asthma is unknown.
Recurrent pneumonia and interstitial lung disease may be complications of reflux, presumably as a result of the failure of airway protective mechanisms to protect the lungs against aspirated gastric contents (513). Reflux causing recurrent pneumonia has been reported in otherwise healthy infants and children (96,514,515). In a retrospective series reviewing the causes of recurrent pneumonia in a heterogenous group of 238 children, the primary cause was aspiration during swallowing in 48%, immunologic disorders in 14%, congenital heart disease in 9%, asthma in 8%, respiratory tract anatomic abnormalities in 8%, unknown in 8%, and reflux in only 6% (516). Small case series suggest that reflux may cause or exacerbate interstitial lung disorders such as idiopathic pulmonary fibrosis (517,518), cystic fibrosis (CF) (519,520), or lung transplant (520,521).
No test can determine whether reflux is causing recurrent pneumonia. An abnormal esophageal pH test may increase the probability that reflux is a cause of recurrent pneumonia but is not proof thereof. A normal esophageal pH test cannot exclude reflux as a cause of pneumonia because if airway protection mechanisms are compromised, even brief reflux episodes that are within the normal range, may be associated with aspiration. Aspiration during swallowing is much more common than aspiration of refluxed material (522). Upper esophageal and pharyngeal pH recordings, and combined pH/MII studies have similar limitations and do not improve the ability to predict GER-related pneumonia (523).
Lipid-laden alveolar macrophages have been used as an indicator of aspiration but the sensitivity and specificity as an indicator of GER-related lung disease is poor (187,524–529). Pepsin content of pulmonary lavage fluid has also been used to document aspiration of gastric contents. Pepsin concentration is elevated in pulmonary lavage from patients with reflux (185,186) but there is substantial overlap with controls (187). Nuclear scintigraphy can detect aspirated gastric contents when images are obtained for 24 hours after enteral administration of a labelled meal. One study reporting that 50% of patients with a variety of respiratory symptoms had aspiration on scintigraphy (169) has not been replicated. It is important to recognize that aspiration also occurs in healthy subjects, especially during sleep (171,172) so the threshold for pathologic aspiration of saliva or gastric contents is not established.
No data are available regarding the predictive value of any diagnostic test for determining which patients will respond to either medical or surgical therapy for GERD. Both medical (530) and surgical (97,531) therapy of GERD have been reported to reduce pulmonary symptoms in certain populations of children with recurrent pneumonia. However, in 1 study of children older than 4 years of age, the number of hospitalizations for respiratory related events increased after antireflux surgery (397). Gastrojejunal feeding provides an alternative approach to prevent reflux-related pneumonia in children with severe NI (532). A recent review of children with severe NI and GERD reported that surgical therapy improved several complications but did not alter the risk of pneumonia (533). The potential benefits of antisecretory therapy for neurologically impaired children with recurrent pneumonia must be balanced against the risk that PPI therapy may increase the incidence of community-acquired pneumonia in these patients, as it does in well children (322). A large double-blind placebo-controlled study to determine the role of PPI therapy in the child with NI is lacking.
In many cases the clinician must make management decisions based on inconclusive diagnostic studies with no certainty regarding outcome. In patients with severely impaired lung function, it may be necessary to proceed with antireflux surgery in an attempt to prevent further pulmonary damage, despite lack of definitive proof that reflux is a cause of pulmonary disease. Alternatively, if minimal pulmonary disease is present, consideration of medical therapy with careful follow-up of pulmonary function may be instituted, although the potential benefits versus risks of PPI are unclear. The efficacy of therapies such as lifestyle changes and prokinetics has not been well studied. A trial of nasogastric feeding may be used to exclude aspiration during swallowing as a potential cause of recurrent disease (532). A trial of nasojejunal therapy may help determine whether surgical antireflux therapy is likely to be beneficial.
The data showing a relation between reflux and upper airway disease are weak, consisting mainly of case descriptions. Airway symptoms attributed to reflux in adults include hoarseness (534), chronic cough (535,536), and the sensation of a lump in the throat (globus sensation) (537,538). Affected adults rarely have typical reflux symptoms. Laryngoscopic findings said to be reflux related include erythema, edema, nodularity, ulceration, granuloma, and cobblestoning (539,540). The sensitivity and specificity of these findings to identify reflux-induced disease are poor (541,542), and a study in children showed poor correlation between laryngeal changes and reflux quantitated by pH probe (543). In a descriptive pediatric study, GERD was more prevalent in children with recurrent laryngotracheitis than in controls (544). In a retrospective study of children undergoing otolaryngologic procedures, an association between esophagitis diagnosed by biopsy and recurrent croup, cough, stridor, laryngomalacia, subglottic stenosis, posterior glottic erythema, and posterior arytenoid erythema was observed (545). Increased frequency of daytime reflux has been described in children with hoarseness (546). One study suggested that reflux contributed to the development of subglottic stenosis in children and to poor outcomes after reparative surgery (547). Increased pharyngeal reflux has been observed in children with laryngomalacia (548,549).
Uncontrolled reports in adults and children showed improved upper airway symptoms after antireflux therapy including fundoplication (193,550–554). However, data from several placebo-controlled studies and careful meta-analyses uniformly have shown no effect of antireflux therapy on upper airway symptoms or signs (555–559). One uncontrolled trial reported a reduction in cough following medical antireflux therapy in children (560). However, a double-blind placebo-controlled study showed no difference in the frequency of symptoms of cough or hoarseness among infants treated with lansoprazole versus those treated with placebo (9).
In summary, descriptive studies report detecting and treating reflux in children with chronic laryngeal signs and symptoms. Upper airway edema, erythema, cobblestoning, and granulomas are neither sensitive nor specific for the diagnosis of GERD. Criteria used for assessing laryngeal findings are variable as are the criteria for diagnosing GERD in published reports. Laryngoscopy is indicated in some of these children to rule out anatomic abnormalities such as laryngeal cleft and functional abnormalities such as vocal-fold dysfunction. Data are insufficient to allow recommending a standard approach to diagnosis, treatment, and follow-up. Extrapolation from adult studies suggests that PPIs will not benefit most children with upper airway symptoms.
Reflux has been suggested as a factor contributing to recurrent sinus disease, pharyngitis, and otitis media (561,562). One uncontrolled case series of children with chronic sinusitis suggested that antireflux treatment dramatically reduced the need for sinus surgery (563). Another series demonstrated more episodes during which pharyngeal pH was <6.0 in children with recurrent rhinopharyngitis compared with controls (564). Two epidemiologic surveys, however, found no difference in the number of ear and sinus infections in infants with and without reflux (17,565). Otalgia has been associated with reflux in children and reported to improve with treatment of reflux (566). There is no proven mechanism by which reflux should cause sinusitis, pharyngitis, and otitis, although direct irritation by refluxed material causing pharyngeal tissue edema has been suggested. The lack of controlled studies and animal models of mechanism makes these studies difficult to translate to pediatric practice.
Case reports and a recent systematic review report a causative association between GERD and dental erosion (414). The severity of dental erosions seems to be correlated with the presence of GERD symptoms and in adults with the severity of proximal esophageal or oral exposure to an acidic pH. Young children and children with NI appear to be at greatest risk. One study in adolescents showed that reflux was associated with an increased incidence of erosion of enamel on the lingual surfaces of the teeth (567). In contrast, another study reported no increased incidence of dental erosions in adolescents with abnormal esophageal pH monitoring (568). Factors other than reflux may also cause similar dental erosions; these include juice drinking, bulimia, and racial and genetic factors that affect the characteristics of enamel and saliva. The approach to evaluation and therapy—specifically, the choice of diagnostic tests, duration of therapy, and criteria for cessation of therapy—is unclear. Close consultation with a qualified pediatric dentist is required. The inspection of the oral cavity in search for dental erosions is advisable in patients with known GERD.
Sandifer syndrome (spasmodic torsional dystonia with arching of the back and opisthotonic posturing, mainly involving the neck and back) is an uncommon but specific manifestation of GERD (13,569,570) that must be differentiated from other causes of abnormal movements including seizures, infantile spasms, and dystonia. The mechanisms underlying this disorder are unproven, but the disorder may be a vagally mediated reflex response to esophageal acid exposure. It resolves with antireflux treatment.
Children with certain underlying disorders are at high risk for developing severe-chronic GERD, compared with those who are otherwise healthy. Although the latter do develop GERD, which on occasion may be severe, the prevalence of severe-chronic GERD is much higher in children with certain underlying conditions, such as NI or anatomic abnormalities, such as repaired EA or HH. These children are more likely to require long-term treatment for healing and maintenance (28,372). Complications of severe GERD occur with greatest frequency in children with underlying GERD-provoking conditions (28,31). Performing studies of various GERD therapies in these groups has inherent difficulties because the populations are heterogeneous; many are unable to report symptoms, some have more than 1 condition, and some require medications to be given by feeding tube. These limit the data available to allow evidence-based recommendations on therapy. However, some studies with quantitative endpoints, for example, endoscopic healing, are available (28,29,131).
The increased frequency and severity of GERD among infants and children with NI including developmental delay are well documented (397,571,572). For example, children with cerebral palsy are at particularly high risk for GERD (571,573–575). Similarly, children with certain genetic syndromes such as Cornelia de Lange and Down syndrome are prone to GERD (576).
The high incidence of severe, chronic GERD is multifactorial in etiology. It is likely that in each child, factors unique to the specific diagnosis and clinical status are responsible. Contributing factors that increase reflux frequency and delay esophageal clearance are chronic supine positioning, abnormal swallowing, heightened gag reflex, abnormal sensory integration, delayed gastric emptying, constipation, obesity, skeletal abnormalities, abnormal muscle tone, and medication side effects. The severity of GERD may result from poor self-protective mechanisms and delayed diagnosis caused by difficulties in obtaining an accurate history of symptoms. Treatment should include lifestyle changes tailored to the unique risk factors of the patient. Changes in feeding volume, consistency, and frequency may be helpful, as may positional changes, control of muscular spasticity, and biofeedback. Antisecretory therapy should be optimized. Long-term treatment with PPIs is often effective for symptom control and maintenance of remission of esophagitis (28,577,578). Baclofen may be useful for reduction of vomiting, but care with regard to dosing and side effects is required (346,347). Elemental diet was shown to improve resistant GERD symptoms in 1 small uncontrolled study that did not differentiate EoE from GERD (579).
Descriptive studies suggest that placement of feeding gastrostomy in children with NI, either by open or laparoscopic surgery, increases the risk of subsequent GERD (580,581). Recent surgical studies comparing open and laparoscopic gastrostomy placement suggest that postoperative development of GERD is less common after laparoscopic and percutaneous endoscopic procedures than open surgical procedures (582–584).
Making a clinical diagnosis of GERD in children with NI is hampered by poor communication with the patient and the frequency of atypical presentations such as anxiety, self-injurious behavior, apparent seizures, and dystonia (585). Evaluation of the child with NI requires a high index of suspicion and must not only confirm the diagnosis but also rule out alternative diagnoses. Contrast GI radiographic studies, upper GI endoscopy and biopsy, metabolic and drug toxicity screening, and pH/impedance studies may be required.
Given the morbidity and high failure rates of antireflux surgery in this group, patients whose symptoms are well controlled on medical therapy may not derive additional benefit from antireflux surgery The relative risks versus benefit of antireflux surgery in children with persistent symptoms despite optimized medical therapy have not been clearly defined (397,586). Patients with respiratory complications of GERD appear to benefit most, but a cause-and-effect relation is difficult to establish, and therefore patient selection is difficult (Section 5.3).
Although pediatric data are scarce, in adults, obesity and/or incremental weight gain have been increasingly shown to be associated with a significantly higher prevalence and severity of GERD, BE, and esophageal adenocarcinoma (265–267).
EA has an incidence of 1 in 3000 live births; thus it is an important cause of chronic-severe GERD in pediatric practice. The esophagus in EA is congenitally dysmotile; it is sometimes foreshortened as a result of surgery or stricture, and a HH is often present (28,29,587), especially in long-gap atresia (588). Significant heart disease, tracheomalacia, or gastric outlet obstruction occurs in up to 18% of these children (587).
Of children and young adults with repaired EA, 50% to 95% have GERD symptoms, including dysphagia and pulmonary symptoms (587,589,590). Esophagitis and BE or some form of metaplasia are prevalent (31,134,589,590), and esophageal adenocarcinoma and squamous cancer are reported in children and adults (589,591–594). A long-term study of 272 surviving children with EA observed no cases of esophageal cancer (595). However, the authors of that study and others (587,589) recommended that patients with EA undergo regular endoscopy to screen for BE and esophageal cancer, given the relatively normal longevity of most patients with EA. In the pre-PPI era, several case series demonstrated a benefit from antireflux surgery, but failure rates of fundoplication are high in children with repaired EA. Medical therapy with PPIs is highly effective in patients with EA and GERD (28).
Patients with achalasia are at increased risk for chronic GERD, esophagitis, and BE following treatment by either pneumatic dilation or myotomy (596,597). The benefit of antireflux therapy at the time of myotomy remains controversial (598). All of the patients with a history of achalasia or a history of EA repair require follow-up for possible complications of GERD, because even those who underwent antireflux surgery are at risk (596). The potential utility of endoscopic surveillance has not been evaluated in these patients.
A higher prevalence of GERD and its complications has been reported in patients with a variety of respiratory disorders including bronchopulmonary dysplasia, idiopathic interstitial fibrosis, and most commonly, CF (500,599,600). In 1 study, 27% of patients with CF younger than 5 years old reported GI symptoms suggestive of reflux (heartburn or regurgitation), compared with only 6% of their healthy siblings (519). However, intraesophageal pH studies in children with CF detect a much higher prevalence of pathologic GE reflux (500), that is, reflux is silent in the majority. Reflux may be silent because GI symptoms are truly absent, or symptoms may be relatively ignored by patients with CF because of their plethora of other problems. Some children with CF consider upper GI symptoms such as heartburn, chest pain, and occasional vomiting, to be part of CF, and therefore may not report them; this results in delayed diagnosis and presentation with complications of GERD (31). There are no trials formally evaluating the benefits and risks of GERD treatments in children with CF, but the high incidence of esophagitis and potential risk of adenocarcinoma makes aggressive treatment reasonable. A retrospective review of fundoplication outcome in patients with CF reported that complications requiring repeat surgery occurred in 12%, recurrent GERD symptoms developed in 48%, and only 28% discontinued GERD medications (601).
Bronchopulmonary dysplasia, a chronic lung disease of infancy with varying degrees of alveolar growth arrest, airway branching abnormalities, and peribronchiolar fibrosis, has been associated with GERD (602). However, more recent studies have not confirmed this association (603). Because most of the studies have been cross-sectional or case-control in design, a cause–effect relation remains to be defined.
Severe GERD is common in patients presenting for transplantation, and a high incidence of GERD occurs following lung transplantation in children and adults (521,604). Complications of GERD are a common source of morbidity in patients with transplantation (521). Pneumonectomy seems to contribute to esophageal and gastric motor dysfunction (605). It has been suggested that in the allograft lung, nonimmune-mediated injury because of reflux contributes to the development of bronchiolitis obliterans syndrome (606).
Although reflux episodes may be more common in infants with bronchopulmonary dysplasia, there is no evidence that GERD therapy affects the clinical course or outcome (603,615). GERD is frequently diagnosed by inadequate criteria in the preterm infant. The relative risks, benefits, and indications for GERD therapy are unclear in premature infants. The long-term risk of GERD in premature infants during adulthood is controversial.
The committee is indebted to Sandy Fasold, Inge Sienaert, and Ilse Van Lier for facilitation of meetings and telephone conference arrangements.
1. Rudolph CD, Mazur LJ, Liptak GS, et al
. Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children: recommendations of the North American Society for Pediatric Gastroenterology and Nutrition. J Pediatr Gastroenterol Nutr 2001; 32(Suppl 2):S1–S31.
2. Vandenplas Y, Belli DC, Benatar A, et al
. The role of cisapride in the treatment of pediatric gastroesophageal reflux. The European Society of Paediatric Gastroenterology, Hepatology and Nutrition. J Pediatr Gastroenterol Nutr 1999; 28:518–528.
3. Vandenplas Y, Belli D, Benhamou P, et al
. A critical appraisal of current management practices for infant regurgitation–recommendations of a working party. Eur J Pediatr 1997; 156:343–357.
4. Fried M, Quigley EM, Hunt RH, et al
. Is an evidence-based approach to creating guidelines always the right one? Nat Clin Pract Gastroenterol Hepatol 2008; 5:60–61.
5. Fried M, Quigley EM, Hunt RH, et al
. Are global guidelines desirable, feasible and necessary? Nat Clin Pract Gastroenterol Hepatol 2008; 5:2–3.
6. Barron JJ, Tan H, Spalding J, et al
. Proton pump inhibitor utilization patterns in infants. J Pediatr Gastroenterol Nutr 2007; 45:421–427.
7. Orenstein SR, Hassall E. Infants and proton pump inhibitors: tribulations, no trials. J Pediatr Gastroenterol Nutr 2007; 45:395–398.
8. Khoshoo V, Edell D, Thompson A, et al
. Are we overprescribing antireflux medications for infants with regurgitation? Pediatrics 2007; 120:946–949.
9. Orenstein SR, Hassall E, Furmaga-Jablonska W, et al
. Multicenter, double-blind, randomized, placebo-controlled trial assessing efficacy & safety of proton pump inhibitor lansoprazole in infants with symptoms of gastroesophageal reflux disease. J Pediatr 2009; 154:514–520.
10. McMurray AR. Three decision-making aids: brainstorming, nominal group, and Delphi technique. J Nurs Staff Dev 1994; 10:62–65.
11. Phillips B. Towards evidence-based medicine for paediatricians. Arch Dis Child 2008; 93:628.
12. Shay S, Tutuian R, Sifrim D, et al
. Twenty-four hour ambulatory simultaneous impedance and pH monitoring: a multicenter report of normal values from 60 healthy volunteers. Am J Gastroenterol 2004; 99:1037–1043.
13. Sherman P, Hassall E, Fagundes-Neto U, et al
. A global evidence-based consensus on the definition of gastroesophageal reflux disease in children. Am J Gastroenterol 2009; 104:1278–1295.
14. Hegar B, Boediarso A, Firmansyah A, et al
. Investigation of regurgitation and other symptoms of gastroesophageal reflux in Indonesian infants. World J Gastroenterol 2004; 10:1795–1797.
15. Miyazawa R, Tomomasa T, Kaneko H, et al
. Prevalence of gastro-esophageal reflux-related symptoms in Japanese infants. Pediatr Int 2002; 44:513–516.
16. Nelson SP, Chen EH, Syniar GM, et al
. Prevalence of symptoms of gastroesophageal reflux during infancy. A pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 1997; 151:569–572.
17. Nelson SP, Chen EH, Syniar GM, et al
. One-year follow-up of symptoms of gastroesophageal reflux during infancy. Pediatric Practice Research Group. Pediatrics 1998; 102:E67.
18. Martin AJ, Pratt N, Kennedy JD, et al
. Natural history and familial relationships of infant spilling to 9 years of age. Pediatrics 2002; 109:1061–1067.
19. Chial HJ, Camilleri M, Williams DE, et al
. Rumination syndrome in children and adolescents: diagnosis, treatment, and prognosis. Pediatrics 2003; 111:158–162.
20. Tutuian R, Castell DO. Rumination documented by using combined multichannel intraluminal impedance and manometry. Clin Gastroenterol Hepatol 2004; 2:340–343.
21. Kawahara H, Dent J, Davidson G. Mechanisms responsible for gastroesophageal reflux in children. Gastroenterology 1997; 113:399–408.
22. Werlin SL, Dodds WJ, Hogan WJ, et al
. Mechanisms of gastroesophageal reflux in children. J Pediatr 1980; 97:244–249.
23. Omari T. Gastro-oesophageal reflux disease in infants and children: new insights, developments and old chestnuts. J Pediatr Gastroenterol Nutr 2005; 41(Suppl 1):S21–S23.
24. Vandenplas Y, Hassall E. Mechanisms of gastroesophageal reflux and gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002; 35:119–136.
25. Murray JA, Camilleri M. The fall and rise of the hiatal hernia. Gastroenterology 2000; 119:1779–1781.
26. Carre IJ, Johnston BT, Thomas PS, et al
. Familial hiatal hernia in a large five generation family confirming true autosomal dominant inheritance. Gut 1999; 45:649–652.
27. Cameron AJ, Higgins JA. Linear gastric erosion. A lesion associated with large diaphragmatic hernia and chronic blood loss anemia. Gastroenterology 1986; 91:338–342.
28. Hassall E, Kerr W, El-Serag HB. Characteristics of children receiving proton pump inhibitors continuously for up to 11 years duration. J Pediatr 2007; 150:262–267.
29. Gunasekaran TS, Hassall EG. Efficacy and safety of omeprazole for severe gastroesophageal reflux in children. J Pediatr 1993; 123:148–154.
30. Cameron AJ. Barrett's esophagus: prevalence and size of hiatal hernia. Am J Gastroenterol 1999; 94:2054–2059.
31. Hassall E. Co-morbidities in childhood Barrett's esophagus. J Pediatr Gastroenterol Nutr 1997; 25:255–260.
32. Jones MP, Sloan SS, Rabine JC, et al
. Hiatal hernia size is the dominant determinant of esophagitis presence and severity in gastroesophageal reflux disease. Am J Gastroenterol 2001; 96:1711–1717.
33. Cameron AJ, Lagergren J, Henriksson C, et al
. Gastroesophageal reflux disease in monozygotic and dizygotic twins. Gastroenterology 2002; 122:55–59.
34. Chak A, Ochs-Balcom H, Falk G, et al
. Familiality in Barrett's esophagus, adenocarcinoma of the esophagus, and adenocarcinoma of the gastroesophageal junction. Cancer Epidemiol Biomarkers Prev 2006; 15:1668–1673.
35. Mohammed I, Cherkas LF, Riley SA, et al
. Genetic influences in gastro-oesophageal reflux disease: a twin study. Gut 2003; 52:1085–1089.
36. Romero Y, Cameron AJ, Locke GR 3rd, et al
. Familial aggregation of gastroesophageal reflux in patients with Barrett's esophagus and esophageal adenocarcinoma. Gastroenterology 1997; 113:1449–1456.
37. Trudgill N. Familial factors in the etiology of gastroesophageal reflux disease, Barrett's esophagus, and esophageal adenocarcinoma. Chest Surg Clin N Am 2002; 12:15–24.
38. Salvatore S, Hauser B, Vandenplas Y. The natural course of gastro-oesophageal reflux. Acta Paediatr 2004; 93:1063–1069.
39. Jadcherla S, Rudolph C. Gastroesophageal reflux in the preterm neonate. Neoreviews 2005; 6:e87–e98.
40. Gupta SK, Hassall E, Chiu YL, et al
. Presenting symptoms of nonerosive and erosive esophagitis in pediatric patients. Dig Dis Sci 2006; 51:858–863.
41. Iacono G, Merolla R, D'Amico D, et al
. Gastrointestinal symptoms in infancy: a population-based prospective study. Dig Liver Dis 2005; 37:432–438.
42. Nelson SP, Chen EH, Syniar GM, et al
. Prevalence of symptoms of gastroesophageal reflux during childhood: a pediatric practice-based survey. Pediatric Practice Research Group. Arch Pediatr Adolesc Med 2000; 154:150–154.
43. Salvatore S, Vandenplas Y. Gastroesophageal reflux and cow milk allergy: is there a link? Pediatrics 2002; 110:972–984.
44. Venter C, Pereira B, Grundy J, et al
. Incidence of parentally reported and clinically diagnosed food hypersensitivity in the first year of life. J Allergy Clin Immunol 2006; 117:1118–1124.
45. Jordan B, Heine RG, Meehan M, et al
. Effect of antireflux medication, placebo and infant mental health intervention on persistent crying: a randomized clinical trial. J Paediatr Child Health 2006; 42:49–58.
46. Moore DJ, Tao BS, Lines DR, et al
. Double-blind placebo-controlled trial of omeprazole in irritable infants with gastroesophageal reflux. J Pediatr 2003; 143:219–223.
47. Chadwick LM, Kurinczuk JJ, Hallam LA, et al
. Clinical and endoscopic predictors of histological oesophagitis in infants. J Paediatr Child Health 1997; 33:388–393.
48. Hyams JS, Ricci A Jr, Leichtner AM. Clinical and laboratory correlates of esophagitis in young children. J Pediatr Gastroenterol Nutr 1988; 7:52–56.
49. Salvatore S, Hauser B, Vandemaele K, et al
. Gastroesophageal reflux disease in infants: how much is predictable with questionnaires, pH-metry, endoscopy and histology? J Pediatr Gastroenterol Nutr 2005; 40:210–215.
50. Vakil N, van Zanten SV, Kahrilas P, et al
. The Montreal definition and classification of gastroesophageal reflux disease: a global evidence-based consensus. Am J Gastroenterol 2006; 101:1900–1920.
51. Orenstein SR, Shalaby TM, Cohn JF. Reflux symptoms in 100 normal infants: diagnostic validity of the infant gastroesophageal reflux questionnaire. Clin Pediatr (Phila) 1996; 35:607–614.
52. Aggarwal S, Mittal SK, Kalra KK, et al
. Infant gastroesophageal reflux disease score: reproducibility and validity in a developing country. Trop Gastroenterol 2004; 25:96–98.
53. Deal L, Gold BD, Gremse DA, et al
. Age-specific questionnaires distinguish GERD symptom frequency and severity in infants and young children: development and initial validation. J Pediatr Gastroenterol Nutr 2005; 41:178–185.
54. Kleinman L, Rothman M, Strauss R, et al
. The infant gastroesophageal reflux questionnaire revised: development and validation as an evaluative instrument. Clin Gastroenterol Hepatol 2006; 4:588–596.
55. Gold BD, Gunasekaran T, Tolia V, et al
. Safety and symptom improvement with esomeprazole in adolescents with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2007; 45:520–529.
56. von Baeyer CL, Spagrud LJ. Systematic review of observational (behavioral) measures of pain for children and adolescents aged 3 to 18 years. Pain 2007; 127:140–150.
57. Stanford EA, Chambers CT, Craig KD. The role of developmental factors in predicting young children's use of a self-report scale for pain. Pain 2006; 120:16–23.
58. Stanford EA, Chambers CT, Craig KD. A normative analysis of the development of pain-related vocabulary in children. Pain 2005; 114:278–284.
59. Beyer JE, McGrath PJ, Berde CB. Discordance between self-report and behavioral pain measures in children aged 3–7 years after surgery. J Pain Symptom Manage 1990; 5:350–356.
60. Shields BJ, Palermo TM, Powers JD, et al
. Predictors of a child's ability to use a visual analogue scale. Child Care Health Dev 2003; 29:281–290.
61. Heine RG, Jordan B, Lubitz L, et al
. Clinical predictors of pathological gastro-oesophageal reflux in infants with persistent distress. J Paediatr Child Health 2006; 42:134–139.
62. Orenstein SR, Cohn JF, Shalaby TM, et al
. Reliability and validity of an infant gastroesophageal reflux questionnaire. Clin Pediatr (Phila) 1993; 32:472–484.
63. Stordal K, Johannesdottir GB, Bentsen BS, et al
. Gastroesophageal reflux disease in children: association between symptoms and pH monitoring. Scand J Gastroenterol 2005; 40:636–640.
64. Tolia V, Bishop PR, Tsou VM, et al
. Multicenter, randomized, double-blind study comparing 10, 20 and 40 mg pantoprazole in children (5–11 years) with symptomatic gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2006; 42:384–391.
65. Vandenplas Y, Goyvaerts H, Helven R, et al
. Gastroesophageal reflux, as measured by 24-hour pH monitoring, in 509 healthy infants screened for risk of sudden infant death syndrome. Pediatrics 1991; 88:834–840.
66. Hochman JA, Favaloro-Sabatier J. Tolerance and reliability of wireless pH monitoring in children. J Pediatr Gastroenterol Nutr 2005; 41:411–415.
67. Croffie JM, Fitzgerald JF, Molleston JP, et al
. Accuracy and tolerability of the Bravo catheter-free pH capsule in patients between the ages of 4 and 18 years. J Pediatr Gastroenterol Nutr 2007; 45:559–563.
68. Gunnarsdottir A, Stenstrom P, Arnbjornsson E. 48-hour wireless oesophageal pH-monitoring in children: are two days better than one? Eur J Pediatr Surg 2007; 17:378–381.
69. Nielsen RG, Bindslev-Jensen C, Kruse-Andersen S, et al
. Severe gastroesophageal reflux disease and cow milk hypersensitivity in infants and children: disease association and evaluation of a new challenge procedure. J Pediatr Gastroenterol Nutr 2004; 39:383–391.
70. Friesen CA, Hodge C, Roberts CC. Accuracy and reproducibility of 12-h esophageal pH monitoring. J Pediatr Gastroenterol Nutr 1991; 12:166–168.
71. Mahajan L, Wyllie R, Oliva L, et al
. Reproducibility of 24-hour intraesophageal pH monitoring in pediatric patients. Pediatrics 1998; 101:260–263.
72. Vandenplas Y, Helven R, Goyvaerts H, et al
. Reproducibility of continuous 24 hour oesophageal pH monitoring in infants and children (see comments). Gut 1990; 31:374–377.
73. Tuttle SG, Grossman MI. Detection of gastro-esophageal reflux by simultaneous measurement of intraluminal pressure and pH. Proc Soc Exp Biol Med 1958; 98:225–227.
74. Johnson LF, Demeester TR. Twenty-four-hour pH monitoring of the distal esophagus. A quantitative measure of gastroesophageal reflux. Am J Gastroenterol 1974; 62:325–332.
75. Johnson LF, DeMeester TR. Development of the 24-hour intraesophageal pH monitoring composite scoring system. J Clin Gastroenterol 1986; 8(Suppl 1):S52–S58.
76. Berquist WE, Ament ME. Upper GI function in sleeping infants. Am Rev Respir Dis 1985; 131:S26–S29.
77. Branicki FJ, Evans DF, Ogilvie AL, et al
. Ambulatory monitoring of oesophageal pH in reflux oesophagitis using a portable radiotelemetry system. Gut 1982; 23:992–998.
78. Chen CL, Orr WC. Analysis of 24-hour esophageal pH monitoring: the effect of state of consciousness. Curr Gastroenterol Rep 2008; 10:258–262.
79. Cucchiara S, Staiano A, Gobio Casali L, et al
. Value of the 24 hour intraoesophageal pH monitoring in children. Gut 1990; 31:129–133.
80. de Caestecker JS, Blackwell JN, Pryde A, et al
. Daytime gastro-oesophageal reflux is important in oesophagitis. Gut 1987; 28:519–526.
81. Boix-Ochoa J, Lafuenta JM, Gil-Vernet JM. Twenty-four hour exophageal pH monitoring in gastroesophageal reflux. J Pediatr Surg 1980; 15:74–78.
82. Vandenplas Y, Derde MP, Piepsz A. Evaluation of reflux episodes during simultaneous esophageal pH monitoring and gastroesophageal reflux scintigraphy in children. J Pediatr Gastroenterol Nutr 1992; 14:256–260.
83. Vandenplas Y, Sacre-Smits L. Continuous 24-hour esophageal pH monitoring in 285 asymptomatic infants 0–15 months old. J Pediatr Gastroenterol Nutr 1987; 6:220–224.
84. Vandenplas Y, Badriul H, Verghote M, et al
. Oesophageal pH monitoring and reflux oesophagitis in irritable infants. Eur J Pediatr 2004; 163:300–304.
85. Sondheimer JM. Continuous monitoring of distal esophageal pH: a diagnostic test for gastroesophageal reflux in infants. J Pediatr 1980; 96:804–807.
86. Wenner J, Johansson J, Johnsson F, et al
. Optimal thresholds and discriminatory power of 48-h wireless esophageal pH monitoring in the diagnosisof GERD. Am J Gastroenterol 2007; 102:1862–1869.
87. Vandenplas Y, Franckx-Goossens A, Pipeleers-Marichal M, et al
. Area under pH 4: advantages of a new parameter in the interpretation of esophageal pH monitoring data in infants. J Pediatr Gastroenterol Nutr 1989; 9:34–39.
88. Sant'Anna AM, Rolland S, Fournet JC, et al
. Eosinophilic esophagitis in children: symptoms, histology and pH probe results. J Pediatr Gastroenterol Nutr 2004; 39:373–377.
89. Steiner SJ, Gupta SK, Croffie JM, et al
. Correlation between number of eosinophils and reflux index on same day esophageal biopsy and 24 hour esophageal pH monitoring. Am J Gastroenterol 2004; 99:801–805.
90. Cinquetti M, Micelli S, Voltolina C, et al
. The pattern of gastroesophageal reflux in asthmatic children. J Asthma 2002; 39:135–142.
91. Semeniuk J, Kaczmarski M. 24-hour esophageal pH monitoring in children with pathological acid gastroesophageal reflux: primary and secondary to food allergy. Part I. Intraesophageal pH values in distal channel; preliminary study and control studies–after 1, 2, 4 and 9 years of clinical observation as well as dietary and pharmacological treatment. Adv Med Sci 2007; 52:199–205.
92. Semeniuk J, Kaczmarski M. 24-hour esophageal pH monitoring in children with pathological acid gastroesophageal reflux: primary and secondary to food allergy. Part II. Intraesophageal pH values in proximal channel; preliminary study and control studies–after 1, 2, 4 and 9 years of clinical observation as well as dietary and pharmacological treatment. Adv Med Sci 2007; 52:206–212.
93. Furuta GT, Liacouras CA, Collins MH, et al
. Eosinophilic esophagitis in children and adults: a systematic review and consensus recommendations for diagnosis and treatment. Gastroenterology 2007; 133:1342–1363.
94. Spechler SJ, Genta RM, Souza RF. Thoughts on the complex relationship between gastroesophageal reflux disease and eosinophilic esophagitis. Am J Gastroenterol 2007; 102:1301–1306.
95. Rothenberg SS, Bratton D, Larsen G, et al
. Laparoscopic fundoplication to enhance pulmonary function in children with severe reactive airway disease and gastroesophageal reflux disease. Surg Endosc 1997; 11:1088–1090.
96. Berquist WE, Rachelefsky GS, Kadden M, et al
. Gastroesophageal reflux-associated recurrent pneumonia and chronic asthma in children. Pediatrics 1981; 68:29–35.
97. Foglia RP, Fonkalsrud EW, Ament ME, et al
. Gastroesophageal fundoplication for the management of chronic pulmonary disease in children. Am J Surg 1980; 140:72–79.
98. Ahrens P, Heller K, Beyer P, et al
. Antireflux surgery in children suffering from reflux-associated respiratory diseases. Pediatr Pulmonol 1999; 28:89–93.
99. Andze GO, Brandt ML, St Vil D, et al
. Diagnosis and treatment of gastroesophageal reflux in 500 children with respiratory symptoms: the value of pH monitoring. J Pediatr Surg 1991; 26:295–299, discussion 299–300.
100. Taghavi SA, Ghasedi M, Saberi-Firoozi M, et al
. Symptom association probability and symptom sensitivity index: preferable but still suboptimal predictors of response to high dose omeprazole. Gut 2005; 54:1067–1071.
101. Hirano I, Richter JE. ACG practice guidelines: esophageal reflux testing. Am J Gastroenterol 2007; 102:668–685.
102. Silny J, Silny J. Intraluminal multiple electric impedance procedure for measurement of gastrointestinal motility. J Gastrointest Motil 1991; 3:151–162.
103. Wenzl TG. Invited review: investigating esophageal reflux with the intraluminal impedance technique. J Pediatr Gastroenterol Nutr 2002; 34:261–268.
104. Peter CS, Wiechers C, Bohnhorst B, et al
. Detection of small bolus volumes using multiple intraluminal impedance in preterm infants. J Pediatr Gastroenterol Nutr 2003; 36:381–384.
105. Skopnik H, Silny J, Heiber O, et al
. Gastroesophageal reflux in infants: evaluation of a new intraluminal impedance technique. J Pediatr Gastroenterol Nutr 1996; 23:591–598.
106. Wenzl TG, Moroder C, Trachterna M, et al
. Esophageal pH monitoring and impedance measurement: a comparison of two diagnostic tests
for gastroesophageal reflux. J Pediatr Gastroenterol Nutr 2002; 34:519–523.
107. Rosen R, Lord C, Nurko S. The sensitivity of multichannel intraluminal impedance and the pH probe in the evaluation of gastroesophageal reflux in children. Clin Gastroenterol Hepatol 2006; 4:167–172.
108. Woodley FW, Mousa H. Acid gastroesophageal reflux reports in infants: a comparison of esophageal pH monitoring and multichannel intraluminal impedance measurements. Dig Dis Sci 2006; 51:1910–1916.
109. Vandenplas Y, Salvatore S, Devreker T, et al
. Gastro-oesophageal reflux disease: oesophageal impedance versus pH monitoring. Acta Paediatr 2007; 96:956–962.
110. Peter CS, Sprodowski N, Ahlborn V, et al
. Inter- and intraobserver agreement for gastroesophageal reflux detection in infants using multiple intraluminal impedance. Biol Neonate 2004; 85:11–14.
111. Dalby K, Nielsen RG, Markoew S, et al
. Reproducibility of 24-hour combined multiple intraluminal impedance (MII) and pH measurements in infants and children. Evaluation of a diagnostic procedure for gastroesophageal reflux disease. Dig Dis Sci 2007; 52:2159–2165.
112. Trachterna M, Wenzl TG, Silny J, et al
. Procedure for the semi-automatic detection of gastro-oesophageal reflux patterns in intraluminal impedance measurements in infants. Med Eng Phys 1999; 21:195–201.
113. Lopez-Alonso M, Moya MJ, Cabo JA, et al
. Twenty-four-hour esophageal impedance-pH monitoring in healthy preterm neonates: rate and characteristics of acid, weakly acidic, and weakly alkaline gastroesophageal reflux. Pediatrics 2006; 118:e299–e308.
114. Wenzl TG. Evaluation of gastroesophageal reflux events in children using multichannel intraluminal electrical impedance. Am J Med 2003; 115(Suppl 3A):161S–165S.
115. Wenzl TG, Schenke S, Peschgens T, et al
. Association of apnea and nonacid gastroesophageal reflux in infants: investigations with the intraluminal impedance technique. Pediatr Pulmonol 2001; 31:144–149.
116. Wenzl TG, Silny J, Schenke S, et al
. Gastroesophageal reflux and respiratory phenomena in infants: status of the intraluminal impedance technique. J Pediatr Gastroenterol Nutr 1999; 28:423–428.
117. Loots CM, Benninga MA, Davidson GP, et al
. Addition of pH-impedance monitoring to standard pH monitoring increases the yield of symptom association analysis in infants and children with gastroesophageal reflux. J Pediatr 2009; 154:248–252.
118. Staiano A, Cucchiara S, Del Giudice E, et al
. Disorders of oesophageal motility in children with psychomotor retardation and gastro-oesophageal reflux. Eur J Pediatr 1991; 150:638–641.
119. Cucchiara S, Campanozzi A, Greco L, et al
. Predictive value of esophageal manometry and gastroesophageal pH monitoring for responsiveness of reflux disease to medical therapy in children. Am J Gastroenterol 1996; 91:680–685.
120. Hillemeier AC, Grill BB, McCallum R, et al
. Esophageal and gastric motor abnormalities in gastroesophageal reflux during infancy. Gastroenterology 1983; 84:741–746.
121. Mattioli G, Sacco O, Repetto P, et al
. Necessity for surgery in children with gastrooesophageal reflux and supraoesophageal symptoms. Eur J Pediatr Surg 2004; 14:7–13.
122. Kahrilas PJ, Shaheen NJ, Vaezi MF, et al
. American Gastroenterological Association Medical Position Statement on the management of gastroesophageal reflux disease. Gastroenterology 2008; 135:1383–1391, 1391 e1–5.
123. Gillett P, Hassall E. Pediatric gastrointestinal mucosal biopsy. Special considerations in children. Gastrointest Endosc Clin N Am 2000; 10:669–712, vi–vii.
124. Lundell LR, Dent J, Bennett JR, et al
. Endoscopic assessment of oesophagitis: clinical and functional correlates and further validation of the Los Angeles classification. Gut 1999; 45:172–180.
125. Hetzel DJ, Dent J, Reed WD, et al
. Healing and relapse of severe peptic esophagitis after treatment with omeprazole. Gastroenterology 1988; 95:903–912.
126. Vieth M, Haringsma J, Delarive J, et al
. Red streaks in the oesophagus in patients with reflux disease: is there a histomorphological correlate? Scand J Gastroenterol 2001; 36:1123–1127.
127. Bytzer P, Havelund T, Hansen JM. Interobserver variation in the endoscopic diagnosis of reflux esophagitis. Scand J Gastroenterol 1993; 28:119–125.
128. Pandolfino JE, Vakil NB, Kahrilas PJ. Comparison of inter- and intraobserver consistency for grading of esophagitis by expert and trainee endoscopists. Gastrointest Endosc 2002; 56:639–643.
129. Rath HC, Timmer A, Kunkel C, et al
. Comparison of interobserver agreement for different scoring systems for reflux esophagitis: impact of level of experience. Gastrointest Endosc 2004; 60:44–49.
130. Boccia G, Manguso F, Miele E, et al
. Maintenance therapy for erosive esophagitis in children after healing by omeprazole: is it advisable? Am J Gastroenterol 2007; 192:1291–1297.
131. Hassall E, Israel D, Shepherd R, et al
. Omeprazole for treatment of chronic erosive esophagitis in children: a multicenter study of efficacy, safety, tolerability and dose requirements. International Pediatric Omeprazole Study Group. J Pediatr 2000; 137:800–807.
132. Dahms BB. Reflux esophagitis: sequelae and differential diagnosis in infants and children including eosinophilic esophagitis. Pediatr Dev Pathol 2004; 7:5–16.
133. Dent J. Microscopic esophageal mucosal injury in nonerosive reflux disease. Clin Gastroenterol Hepatol 2007; 5:4–16.
134. Hassall E. Esophageal metaplasia: definition and prevalence in childhood. Gastrointest Endosc 2006; 64:676–677.
135. van Malenstein H, Farre R, Sifrim D. Esophageal dilated intercellular spaces (DIS) and nonerosive reflux disease. Am J Gastroenterol 2008; 103:1021–1028.
136. Pope C. Is it necessary to perform a biopsy in erosive esophagitis? In: Giuli R TG, DeMeester TR, Galmiche J-P, eds. The Esophageal Mucosa
. Amsterdam: Elsevier Press; 1994:303–8.
137. Behar J, Sheahan D. Histologic abnormalities in reflux esophagitis. Arch Pathol 1975; 99:387–391.
138. Ismail-Beigi F, Horton PF, Pope CE 2nd. Histological consequences of gastroesophageal reflux in man. Gastroenterology 1970; 58:163–174.
139. Weinstein WM, Bogoch ER, Bowes KL. The normal human esophageal mucosa: a histological reappraisal. Gastroenterology 1975; 68:40–44.
140. Heine RG, Cameron DJ, Chow CW, et al
. Esophagitis in distressed infants: poor diagnostic agreement between esophageal pH monitoring and histopathologic findings. J Pediatr 2002; 140:14–19.
141. Ravelli AM, Villanacci V, Ruzzenenti N, et al
. Dilated intercellular spaces: a major morphological feature of esophagitis. J Pediatr Gastroenterol Nutr 2006; 42:510–515.
142. Hill DJ, Heine RG, Cameron DJ, et al
. Role of food protein intolerance in infants with persistent distress attributed to reflux esophagitis. J Pediatr 2000; 136:641–647.
143. Orenstein SR, Shalaby TM, Kelsey SF, et al
. Natural history of infant reflux esophagitis: symptoms and morphometric histology during one year without pharmacotherapy. Am J Gastroenterol 2006; 101:628–640.
144. Boyce HW. Endoscopic definitions of esophagogastric junction regional anatomy. Gastrointest Endosc 2000; 51:586–592.
145. McClave SA, Boyce HW Jr, Gottfried MR. Early diagnosis of columnar-lined esophagus: a new endoscopic diagnostic criterion. Gastrointest Endosc 1987; 33:413–416.
146. Ofman JJ, Shaheen NJ, Desai AA, et al
. The quality of care in Barrett's esophagus: endoscopist and pathologist practices. Am J Gastroenterol 2001; 96:876–881.
147. Gordon C, Kang JY, Neild PJ, et al
. The role of the hiatus hernia in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2004; 20:719–732.
148. Weinstein WM, Ippoliti AF. The diagnosis of Barrett's esophagus: goblets, goblets, goblets. Gastrointest Endosc 1996; 44:91–95.
149. Hassall E. Cardia-type mucosa as an esophageal metaplastic condition in children:“Barrett's esophagus, intestinal metaplasia-negative?”. J Pediatr Gastroenterol Nutr 2008; 47:102–106.
150. Peitz U, Vieth M, Pross M, et al
. Cardia-type metaplasia arising in the remnant esophagus after cardia resection. Gastrointest Endosc 2004; 59:810–817.
151. Siebert JJ, Byrne WJ, Euler AR, et al
. Gastroesophageal reflux - the acid test: scintigraphy or the pH probe? Am J Roentgenol 1983; 140:1087–1090.
152. Stephen TC, Younoszai MK, Massey MP, et al
. Diagnosis of gastroesophageal reflux in pediatrics. J Ky Med Assoc 1994; 92:188–191.
153. Meyers WF, Roberts CC, Johnson DG, et al
. Value of tests for evaluation of gastroesophageal reflux in children. J Pediatr Surg 1985; 20:515–520.
154. Thompson JK, Koehler RE, Richter JE. Detection of gastroesophageal reflux: value of barium studies compared with 24-hr pH monitoring. AJR Am J Roentgenol 1994; 162:621–626.
155. Gupta JP, Kumar A, Jain AK, et al
. Gastro-esophageal reflux disease (GERD): an appraisal of different tests for diagnosis. J Assoc Physicians India 1990; 38(Suppl 1):S699–S702.
156. Chen MY, Ott DJ, Sinclair JW, et al
. Gastroesophageal reflux disease: correlation of esophageal pH testing and radiographic findings. Radiology 1992; 185:483–486.
157. Aksglaede K, Pedersen JB, Lange A, et al
. Gastro-esophageal reflux demonstrated by radiography in infants less than 1 year of age. Comparison with pH monitoring. Acta Radiol 2003; 44:136–138.
158. Simanovsky N, Buonomo C, Nurko S. The infant with chronic vomiting: the value of the upper GI series. Pediatr Radiol 2002; 32:549–550, discussion 551.
159. Di Lorenzo C, Piepsz A, Ham H, et al
. Gastric emptying with gastro-oesophageal reflux. Arch Dis Child 1987; 62:449–453.
160. Papaila JG, Wilmot D, Grosfeld JL, et al
. Increased incidence of delayed gastric emptying in children with gastroesophageal reflux. A prospective evaluation. Arch Surg 1989; 124:933–936.
161. Hillemeier AC, Lange R, McCallum R, et al
. Delayed gastric emptying in infants with gastroesophageal reflux. J Pediatr 1981; 98:190–193.
162. Seibert JJ, Byrne WJ, Euler AR, et al
. Gastroesophageal reflux- the acid test: scintigraphy or the pH probe? AJR Am J Roentgenol 1983; 140:1087–1090.
163. Arasu TS, Wyllie R, Fitzgerald JF, et al
. Gastroesophageal reflux in infants and children comparative accuracy of diagnostic methods. J Pediatr 1980; 96:798–803.
164. Tolia V, Kauffman RE. Comparison of evaluation of gastroesophageal reflux in infants using different feedings during intraesophageal pH monitoring. J Pediatr Gastroenterol Nutr 1990; 10:426–429.
165. Balson BM, Kravitz EK, McGeady SJ. Diagnosis and treatment of gastroesophageal reflux in children and adolescents with severe asthma. Ann Allergy Asthma Immunol 1998; 81:159–164.
166. Vandenplas Y, Belli D, Boige N, et al
. A standardized protocol for the methodology of esophageal pH monitoring and interpretation of the data for the diagnosis of gastroesophageal reflux (ESPGAN statement). J Pediatr Gastroenterol Nutr 1992; 14:467–471.
167. Ghaed N, Stein MR. Assessment of a technique for scintigraphic monitoring of pulmonary aspiration of gastric contents in asthmatics with gastroesophageal reflux. Ann Allergy 1979; 42:306–308.
168. Fawcett HD, Hayden CK, Adams JC, et al
. How useful is gastroesophageal reflux scintigraphy in suspected childhood aspiration? Pediatr Radiol 1988; 18:311–313.
169. Ravelli AM, Panarotto MB, Verdoni L, et al
. Pulmonary aspiration shown by scintigraphy in gastroesophageal reflux-related respiratory disease. Chest 2006; 130:1520–1526.
170. McVeagh P, Howman-Giles R, Kemp A. Pulmonary aspiration studied by radionuclide milk scanning and barium swallow roentgenography. Am J Dis Child 1987; 141:917–921.
171. Gleeson K, Eggli DF, Maxwell SL. Quantitative aspiration during sleep in normal subjects. Chest 1997; 111:1266–1272.
172. Huxley EJ, Viroslav J, Gray WR, et al
. Pharyngeal aspiration in normal adults and patients with depressed consciousness. Am J Med 1978; 64:564–568.
173. van Wijk MP, Benninga MA, Dent J, et al
. Effect of body position changes on postprandial gastroesophageal reflux and gastric emptying in the healthy premature neonate. J Pediatr 2007; 151:585–590, 590 e1–2.
174. Gatti C, di Abriola FF, Dall'Oglio L, et al
. Is the 13C-acetate breath test a valid procedure to analyse gastric emptying in children? J Pediatr Surg 2000; 35:62–65.
175. Van Den Driessche M, Peeters K, Marien P, et al
. Gastric emptying in formula-fed and breast-fed infants measured with the 13C-octanoic acid breath test. J Pediatr Gastroenterol Nutr 1999; 29:46–51.
176. Van Den Driessche M. Study of gastro-intestinal motility in infants and children using 13
C breath tests. In: Faculty of Medicine
. Leuven: Catholic University Leuven; 2001:129.
177. Westra SJ, Wolf BH, Staalman CR. Ultrasound diagnosis of gastroesophageal reflux and hiatal hernia in infants and young children. J Clin Ultrasound 1990; 18:477–485.
178. Jang HS, Lee JS, Lim GY, et al
. Correlation of color Doppler sonographic findings with pH measurements in gastroesophageal reflux in children. J Clin Ultrasound 2001; 29:212–217.
179. Tipnis NA, Liu J, Puckett JL, et al
. Common cavity pressure during gastroesophageal reflux: reassessment using simultaneous pressure, impedance, and ultrasound imaging. Am J Physiol Gastrointest Liver Physiol 2006; 290:G1149–G1156.
180. Tack J. Review article: the role of bile and pepsin in the pathophysiology and treatment of gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2006; 24(Suppl 2):S10–S16.
181. Abd El-Fattah AM, Abdul Maksoud GA, Ramadan AS, et al
. Pepsin assay: a marker for reflux in pediatric glue ear. Otolaryngol Head Neck Surg 2007; 136:464–470.
182. He Z, O'Reilly RC, Bolling L, et al
. Detection of gastric pepsin in middle ear fluid of children with otitis media. Otolaryngol Head Neck Surg 2007; 137:59–64.
183. Crapko M, Kerschner JE, Syring M, et al
. Role of extra-esophageal reflux in chronic otitis media with effusion. Laryngoscope 2007; 117:1419–1423.
184. O'Reilly RC, He Z, Bloedon E, et al
. The role of extraesophageal reflux in otitis media in infants and children. Laryngoscope 2008; 118:1–9.
185. Farhath S, Aghai ZH, Nakhla T, et al
. Pepsin, a reliable marker of gastric aspiration, is frequently detected in tracheal aspirates from premature ventilated neonates: relationship with feeding and methylxanthine therapy. J Pediatr Gastroenterol Nutr 2006; 43:336–341.
186. Farrell S, McMaster C, Gibson D, et al
. Pepsin in bronchoalveolar lavage fluid: a specific and sensitive method of diagnosing gastro-oesophageal reflux-related pulmonary aspiration. J Pediatr Surg 2006; 41:289–293.
187. Starosta V, Kitz R, Hartl D, et al
. Bronchoalveolar pepsin, bile acids, oxidation, and inflammation in children with gastroesophageal reflux disease. Chest 2007; 132:1557–1564.
188. Orel R, Vidmar G. Do acid and bile reflux into the esophagus simultaneously? Temporal relationship between duodenogastro-esophageal reflux and esophageal pH. Pediatr Int 2007; 49:226–231.
189. Hoffman I, Tertychnyy A, Ectors N, et al
. Duodenogastro-esophageal reflux in children with refractory gastro-esophageal reflux disease. J Pediatr 2007; 151:307–311.
190. Orel R, Brecelj J, Homan M, et al
. Treatment of oesophageal bile reflux in children: the results of a prospective study with omeprazole. J Pediatr Gastroenterol Nutr 2006; 42:376–383.
191. Armstrong D, Marshall JK, Chiba N, et al
. Canadian Consensus Conference on the management of gastroesophageal reflux disease in adults - update 2004. Can J Gastroenterol 2005; 19:15–35.
192. Irwin RS. Chronic cough due to gastroesophageal reflux disease: ACCP evidence-based clinical practice guidelines
. Chest 2006; 129:80S–94S.
193. Ours TM, Kavuru MS, Schilz RJ, et al
. A prospective evaluation of esophageal testing and a double-blind, randomized study of omeprazole in a diagnostic and therapeutic algorithm for chronic cough. Am J Gastroenterol 1999; 94:3131–3138.
194. Cremonini F, Wise J, Moayyedi P, et al
. Diagnostic and therapeutic use of proton pump inhibitors in non-cardiac chest pain: a metaanalysis. Am J Gastroenterol 2005; 100:1226–1232.
195. Talley NJ, Vakil N. Guidelines for the management of dyspepsia. Am J Gastroenterol 2005; 100:2324–2337.
196. Numans ME, Lau J, de Wit NJ, et al
. Short-term treatment with proton-pump inhibitors as a test for gastroesophageal reflux disease: a meta-analysis of diagnostic test characteristics. Ann Intern Med 2004; 140:518–527.
197. Talley NJ, Armstrong D, Junghard O, et al
. Predictors of treatment response in patients with non-erosive reflux disease. Aliment Pharmacol Ther 2006; 24:371–376.
198. Kahrilas PJ, Falk GW, Johnson DA, et al
. Esomeprazole improves healing and symptom resolution as compared with omeprazole in reflux oesophagitis patients: a randomized controlled trial. The Esomeprazole Study Investigators. Aliment Pharmacol Ther 2000; 14:1249–1258.
199. Richter JE, Kahrilas PJ, Johanson J, et al
. Efficacy and safety of esomeprazole compared with omeprazole in GERD patients with erosive esophagitis: a randomized controlled trial. Am J Gastroenterol 2001; 96:656–665.
200. Vakil N. Review article: how valuable are proton-pump inhibitors in establishing a diagnosis of gastro-oesophageal reflux disease? Aliment Pharmacol Ther 2005; 22(Suppl 1):S64–S69.
201. Heacock HJ, Jeffery HE, Baker JL, et al
. Influence of breast versus formula milk on physiological gastroesophageal reflux in healthy, newborn infants. J Pediatr Gastroenterol Nutr 1992; 14:41–46.
202. Osatakul S, Sriplung H, Puetpaiboon A, et al
. Prevalence and natural course of gastroesophageal reflux symptoms: a 1-year cohort study in Thai infants. J Pediatr Gastroenterol Nutr 2002; 34:63–67.
203. Barak M, Lahav S, Mimouni FB, et al
. The prevalence of regurgitations in the first 2 days of life in human milk- and formula-fed term infants. Breastfeed Med 2006; 1:168–171.
204. Forget P, Arends JW. Cow's milk protein allergy and gastro-oesophageal reflux. Eur J Pediatr 1985; 144:298–300.
205. Semeniuk J, Kaczmarski M. Gastroesophageal reflux in children and adolescents. Clinical aspects with special respect to food hypersensitivity. Adv Med Sci 2006; 51:327–335.
206. Iacono G, Carroccio A, Cavataio F, et al
. Gastroesophageal reflux and cow's milk allergy in infants: a prospective study. J Allergy Clin Immunol 1996; 97:822–827.
207. Hill DJ, Cameron DJ, Francis DE, et al
. Challenge confirmation of late-onset reactions to extensively hydrolyzed formulas in infants with multiple food protein intolerance. J Allergy Clin Immunol 1995; 96:386–394.
208. Orenstein S, McGowan J. Efficacy of conservative therapy as taught in the primary care setting for symptoms suggesting infant gastroesophageal reflux. J Pediatr 2008; 152:310–314.
209. Isolauri E, Tahvanainen A, Peltola T, et al
. Breast-feeding of allergic infants. J Pediatr 1999; 134:27–32.
210. Vance GH, Lewis SA, Grimshaw KE, et al
. Exposure of the fetus and infant to hens' egg ovalbumin via the placenta and breast milk in relation to maternal intake of dietary egg. Clin Exp Allergy 2005; 35:1318–1326.
211. Khoshoo V, Ross G, Brown S, et al
. Smaller volume, thickened formulas in the management of gastroesophageal reflux in thriving infants. J Pediatr Gastroenterol Nutr 2000; 31:554–556.
212. Vandenplas Y, Sacre L. Milk-thickening agents as a treatment for gastroesophageal reflux [published erratum appears in Clin Pediatr (Phila)
. 1987; 26:148]. Clin Pediatr (Phila)
213. Bailey DJ, Andres JM, Danek GD, et al
. Lack of efficacy of thickened feeding as treatment for gastroesophageal reflux. J Pediatr 1987; 110:187–189.
214. Orenstein SR, Magill HL, Brooks P. Thickening of infant feedings for therapy of gastroesophageal reflux. J Pediatr 1987; 110:181–186.
215. Craig WR, Hanlon-Dearman A, Sinclair C, Taback S, Moffatt M. Metoclopramide, thickened feedings, and positioning for gastro-oesophageal reflux in children under two years. Cochrane Database Syst Rev
216. Xinias I, Mouane N, Le Luyer B, et al
. Cornstarch thickened formula reduces oesophageal acid exposure time in infants. Dig Liver Dis 2005; 37:23–27.
217. Corvaglia L, Ferlini M, Rotatori R, et al
. Starch thickening of human milk is ineffective in reducing the gastroesophageal reflux in preterm infants: a crossover study using intraluminal impedance. J Pediatr 2006; 148:265–268.
218. Orenstein SR, Shalaby TM, Putnam PE. Thickened feedings as a cause of increased coughing when used as therapy for gastroesophageal reflux in infants. J Pediatr 1992; 121:913–915.
219. Chao HC, Vandenplas Y. Comparison of the effect of a cornstarch thickened formula and strengthened regular formula on regurgitation, gastric emptying and weight gain in infantile regurgitation. Dis Esophagus 2007; 20:155–160.
220. Vandenplas Y, Hachimi-Idrissi S, Casteels A, et al
. A clinical trial with an “anti-regurgitation” formula. Eur J Pediatr 1994; 153:419–423.
221. Moukarzel AA, Abdelnour H, Akatcherian C. Effects of a prethickened formula on esophageal pH and gastric emptying of infants with GER. J Clin Gastroenterol 2007; 41:823–829.
222. Borrelli O, Salvia G, Campanozzi A, et al
. Use of a new thickened formula for treatment of symptomatic gastrooesophageal reflux in infants. Ital J Gastroenterol Hepatol 1997; 29:237–242.
223. Chao HC, Vandenplas Y. Effect of cereal-thickened formula and upright positioning on regurgitation, gastric emptying, and weight gain in infants with regurgitation. Nutrition 2007; 23:23–28.
224. Miyazawa R, Tomomasa T, Kaneko H, et al
. Effects of pectin liquid on gastroesophageal reflux disease in children with cerebral palsy. BMC Gastroenterol 2008; 8:11.
225. Miyazawa R, Tomomasa T, Kaneko H, et al
. Effect of formula thickened with reduced concentration of locust bean gum on gastroesophageal reflux. Acta Paediatr 2007; 96:910–914.
226. Vanderhoof JA, Moran JR, Harris CL, et al
. Efficacy of a pre-thickened infant formula: a multicenter, double-blind, randomized, placebo-controlled parallel group trial in 104 infants with symptomatic gastroesophageal reflux. Clin Pediatr (Phila) 2003; 42:483–495.
227. Hegar B, Rantos R, Firmansyah A, et al
. Natural evolution of infantile regurgitation versus the efficacy of thickened formula. J Pediatr Gastroenterol Nutr 2008; 47:26–30.
228. Bosscher D, Van Caillie-Bertrand M, Deelstra H. Do thickening properties of locust bean gum affect the amount of calcium, iron and zinc available for absorption from infant formula? In vitro studies. Int J Food Sci Nutr 2003; 54:261–268.
229. Bosscher D, Van Caillie-Bertrand M, Van Dyck K, et al
. Thickening infant formula with digestible and indigestible carbohydrate: availability of calcium, iron, and zinc in vitro. J Pediatr Gastroenterol Nutr 2000; 30:373–378.
230. Levtchenko E, Hauser B, Vandenplas Y. Nutritional value of an “anti-regurgitation” formula. Acta Gastroenterol Belg 1998; 61:285–287.
231. Ferry GD, Selby M, Pietro TJ. Clinical response to short-term nasogastric feeding in infants with gastroesophageal reflux and growth failure. J Pediatr Gastroenterol Nutr 1983; 2:57–61.
232. Meyers WF, Herbst JJ. Effectiveness of positioning therapy for gastroesophageal reflux. Pediatrics 1982; 69:768–772.
233. Vandenplas Y, Sacre-Smits L. Seventeen-hour continuous esophageal pH monitoring in the newborn: evaluation of the influence of position in asymptomatic and symptomatic babies. J Pediatr Gastroenterol Nutr 1985; 4:356–361.
234. Tobin JM, McCloud P, Cameron DJ. Posture and gastro-oesophageal reflux: a case for left lateral positioning. Arch Dis Child 1997; 76:254–258.
235. Corvaglia L, Rotatori R, Ferlini M, et al
. The effect of body positioning on gastroesophageal reflux in premature infants: evaluation by combined impedance and pH monitoring. J Pediatr 2007; 151:591–596, 596 e1.
236. Bhat RY, Rafferty GF, Hannam S, et al
. Acid gastroesophageal reflux in convalescent preterm infants: effect of posture and relationship to apnea. Pediatr Res 2007; 62:620–623.
237. Orenstein SR. Prone positioning in infant gastroesophageal reflux: is elevation of the head worth the trouble? J Pediatr 1990; 117:184–187.
238. Jeske HC, Borovicka J, von Goedecke A, et al
. The influence of postural changes on gastroesophageal reflux and barrier pressure in nonfasting individuals. Anesth Analg 2005; 101:597–600. Table of contents.
239. Bagucka B, DeSchepper J, Peelman M, et al
. Acid gastroesophageal reflux in the 10°-reverse-Trendelenburg position in supine sleeping infants. Acta Pediatri Taiwan 1999; 40:298–301.
240. Orenstein SR, Whitington PF, Orenstein DM. The infant seat as treatment for gastroesophageal reflux. N Engl J Med 1983; 309:760–763.
241. Vandenplas Y, Hauser B. Gastro-oesophageal reflux, sleep pattern, apparent life threatening event and sudden infant death. The point of view of a gastro-enterologist. Eur J Pediatr 2000; 159:726–729.
242. Oyen N, Markestad T, Skaerven R, et al
. Combined effects of sleeping position and prenatal risk factors in sudden infant death syndrome: the Nordic Epidemiological SIDS Study. Pediatrics 1997; 100:613–621.
243. Skadberg BT, Morild I, Markestad T. Abandoning prone sleeping: effect on the risk of sudden infant death syndrome. J Pediatr 1998; 132:340–343.
244. Adams EJ, Chavez GF, Steen D, et al
. Changes in the epidemiologic profile of sudden infant death syndrome as rates decline among California infants: 1990–1995. Pediatrics 1998; 102:1445–1451.
245. Katz LC, Just R, Castell DO. Body position affects recumbent postprandial reflux. J Clin Gastroenterol 1994; 18:280–283.
246. Khoury RM, Camacho-Lobato L, Katz PO, et al
. Influence of spontaneous sleep positions on nighttime recumbent reflux in patients with gastroesophageal reflux disease. Am J Gastroenterol 1999; 94:2069–2073.
247. Omari TI, Rommel N, Staunton E, et al
. Paradoxical impact of body positioning on gastroesophageal reflux and gastric emptying in the premature neonate. J Pediatr 2004; 145:194–200.
248. American Academy of Pediatrics Task Force on Sudden Infant Death Syndrome. The changing concept of sudden infant death syndrome: diagnostic coding shifts, controversies regarding the sleeping environment, and new variables to consider in reducing risk. Pediatrics
249. Kaltenbach T, Crockett S, Gerson LB. Are lifestyle measures effective in patients with gastroesophageal reflux disease? An evidence-based approach. Arch Intern Med 2006; 166:965–971.
250. Austin GL, Thiny MT, Westman EC, et al
. A very low-carbohydrate diet improves gastroesophageal reflux and its symptoms. Dig Dis Sci 2006; 51:1307–1312.
251. Peluso L, Vanek VW. Efficacy of gastric bypass in the treatment of obesity-related comorbidities. Nutr Clin Pract 2007; 22:22–28.
252. Piesman M, Hwang I, Maydonovitch C, et al
. Nocturnal reflux episodes following the administration of a standardized meal. Does timing matter? Am J Gastroenterol 2007; 102:2128–2134.
253. Vandenplas Y, De Wolf D, Sacre L. Influence of xanthines on gastroesophageal reflux in infants at risk for sudden infant death syndrome. Pediatrics 1986; 77:807–810.
254. Pehl C, Pfeiffer A, Wendl B, et al
. The effect of decaffeination of coffee on gastro-oesophageal reflux in patients with reflux disease. Aliment Pharmacol Ther 1997; 11:483–486.
255. Wendl B, Pfeiffer A, Pehl C, et al
. Effect of decaffeination of coffee or tea on gastro-oesophageal reflux. Aliment Pharmacol Ther 1994; 8:283–287.
256. Brazer SR, Onken JE, Dalton CB, et al
. Effect of different coffees on esophageal acid contact time and symptoms in coffee-sensitive subjects. Physiol Behav 1995; 57:563–567.
257. Chang CS, Poon SK, Lien HC, et al
. The incidence of reflux esophagitis among the Chinese. Am J Gastroenterol 1997; 92:668–671.
258. Castiglione F, Emde C, Armstrong D, et al
. Oesophageal pH-metry: should meals be standardized? Scand J Gastroenterol 1992; 27:350–354.
259. Murphy DW, Castell DO. Chocolate and heartburn: evidence of increased esophageal acid exposure after chocolate ingestion. Am J Gastroenterol 1988; 83:633–636.
260. Wright LE, Castell DO. The adverse effect of chocolate on lower esophageal sphincter pressure. Am J Dig Dis 1975; 20:703–707.
261. Bartlett DW, Evans DF, Smith BG. Oral regurgitation after reflux provoking meals: a possible cause of dental erosion? J Oral Rehabil 1997; 24:102–108.
262. Nebel OT, Fornes MF, Castell DO. Symptomatic gastroesophageal reflux: incidence and precipitating factors. Am J Dig Dis 1976; 21:953–956.
263. Allen ML, Mellow MH, Robinson MG, et al
. The effect of raw onions on acid reflux and reflux symptoms. Am J Gastroenterol 1990; 85:377–380.
264. Bulat R, Fachnie E, Chauhan U, et al
. Lack of effect of spearmint on lower oesophageal sphincter function and acid reflux in healthy volunteers. Aliment Pharmacol Ther 1999; 13:805–812.
265. Jacobson BC, Somers SC, Fuchs CS, et al
. Body-mass index and symptoms of gastroesophageal reflux in women. N Engl J Med 2006; 354:2340–2348.
266. El-Serag H. Role of obesity in GORD-related disorders. Gut 2008; 57:281–284.
267. Gerson LB. A little weight gain, how much gastroesophageal reflux disease? Gastroenterology 2006; 131:1644–1646, discussion 1646.
268. Veugelers PJ, Porter GA, Guernsey DL, et al
. Obesity and lifestyle risk factors for gastroesophageal reflux disease, Barrett esophagus and esophageal adenocarcinoma. Dis Esophagus 2006; 19:321–328.
269. Whiteman DC, Sadeghi S, Pandeya N, et al
. Combined effects of obesity, acid reflux and smoking on the risk of adenocarcinomas of the oesophagus. Gut 2008; 57:173–180.
270. Avidan B, Sonnenberg A, Schnell TG, et al
. Walking and chewing reduce postprandial acid reflux. Aliment Pharmacol Ther 2001; 15:151–155.
271. Moazzez R, Bartlett D, Anggiansah A. The effect of chewing sugar-free gum on gastro-esophageal reflux. J Dent Res 2005; 84:1062–1065.
272. Smoak BR, Koufman JA. Effects of gum chewing on pharyngeal and esophageal pH. Ann Otol Rhinol Laryngol 2001; 110:1117–1119.
273. Stanciu C, Bennett JR. Effects of posture on gastro-oesophageal reflux. Digestion 1977; 15:104–109.
274. Hamilton JW, Boisen RJ, Yamamoto DT, et al
. Sleeping on a wedge diminishes exposure of the esophagus to refluxed acid. Dig Dis Sci 1988; 33:518–522.
275. Johnson LF, DeMeester TR. Evaluation of elevation of the head of the bed, bethanechol, and antacid form tablets on gastroesophageal reflux. Dig Dis Sci 1981; 26:673–680.
276. Meining A, Classen M. The role of diet and lifestyle measures in the pathogenesis and treatment of gastroesophageal reflux disease. Am J Gastroenterol 2000; 95:2692–2697.
277. Sutphen JL, Dillard VL. Effect of ranitidine on twenty-four-hour gastric acidity in infants. J Pediatr 1989; 114:472–474.
278. Mallet E, Mouterde O, Dubois F, et al
. Use of ranitidine in young infants with gastro-oesophageal reflux. Eur J Clin Pharmacol 1989; 36:641–642.
279. Orenstein SR, Blumer JL, Faessel HM, et al
. Ranitidine, 75 mg, over-the-counter dose: pharmacokinetic and pharmacodynamic effects in children with symptoms of gastro-oesophageal reflux. Aliment Pharmacol Ther 2002; 16:899–907.
280. Hyman PE, Garvey TQ 3rd, Abrams CE. Tolerance to intravenous ranitidine. J Pediatr 1987; 110:794–796.
281. Nwokolo CU, Smith JT, Gavey C, et al
. Tolerance during 29 days of conventional dosing with cimetidine, nizatidine, famotidine or ranitidine. Aliment Pharmacol Ther 1990; 4(Suppl 1):S29–S45.
282. Wilder-Smith CH, Ernst T, Gennoni M, et al
. Tolerance to oral H2-receptor antagonists. Dig Dis Sci 1990; 35:976–983.
283. Chiba N, De Gara CJ, Wilkinson JM, et al
. Speed of healing and symptom relief in grade II to IV gastroesophageal reflux disease: a meta-analysis. Gastroenterology 1997; 112:1798–1810.
284. McCarty-Dawson D, Sue SO, Morrill B, et al
. Ranitidine versus cimetidine in the healing of erosive esophagitis. Clin Ther 1996; 18:1150–1160.
285. Stacey JH, Miocevich ML, Sacks GE. The effect of ranitidine (as effervescent tablets) on the quality of life of GORD patients. Br J Clin Pract 1996; 50:190–194, 196.
286. Sabesin SM, Berlin RG, Humphries TJ, et al
. Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group. Arch Intern Med 1991; 151:2394–2400.
287. Cucchiara S, Gobio-Casali L, Balli F, et al
. Cimetidine treatment of reflux esophagitis in children: an Italian multicentric study. J Pediatr Gastroenterol Nutr 1989; 8:150–156.
288. Simeone D, Caria MC, Miele E, et al
. Treatment of childhood peptic esophagitis: a double-blind placebo-controlled trial of nizatidine. J Pediatr Gastroenterol Nutr 1997; 25:51–55.
289. Kelly DA. Do H2 receptor antagonists have a therapeutic role in childhood? J Pediatr Gastroenterol Nutr 1994; 19:270–276.
290. Berezin S, Medow MS, Glassman M, et al
. Use of the intraesophageal acid perfusion test in provoking nonspecific chest pain in children. J Pediatr 1989; 115:709–712.
291. Cucchiara S, Minella R, Iervolino C, et al
. Omeprazole and high dose ranitidine in the treatment of refractory reflux oesophagitis. Arch Dis Child 1993; 69:655–659.
292. DeAngelis G, Banchini G. Ranitidine in paediatric patients, a personal experience. Clin Trials 1989; 26:370–375.
293. Orenstein SR, Shalaby TM, Devandry SN, et al
. Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial. Aliment Pharmacol Ther 2003; 17:1097–1107.
294. Orenstein SR, Gremse DA, Pantaleon CD, et al
. Nizatidine for the treatment of pediatric gastroesophageal reflux symptoms: an open-label, multiple-dose, randomized, multicenter clinical trial in 210 children. Clin Ther 2005; 27:472–483.
295. van Pinxteren B, Numans ME, Bonis PA, Lau J. Short-term treatment with proton pump inhibitors, H2
-receptor antagonists and prokinetics for gastro-oesophageal reflux disease-like symptoms and endoscopy negative reflux disease. Cochrane Database Syst Rev
296. Khan M, Santana J, Donnellan C, Preston C, Moayyedi P. Medical treatments in the short term management of reflux oesophagitis. Cochrane Database Syst Rev
297. Garcia Rodriguez LA, Wallander MA, Stricker BH. The risk of acute liver injury associated with cimetidine and other acid-suppressing anti-ulcer drugs. Br J Clin Pharmacol 1997; 43:183–188.
298. Ribeiro JM, Lucas M, Baptista A, et al
. Fatal hepatitis associated with ranitidine. Am J Gastroenterol 2000; 95:559–560.
299. Garcia Rodriguez LA, Jick H. Risk of gynaecomastia associated with cimetidine, omeprazole, and other antiulcer drugs. BMJ 1994; 308:503–506.
300. Champion G, Richter JE, Vaezi MF, et al
. Duodenogastroesophageal reflux: relationship to pH and importance in Barrett's esophagus. Gastroenterology 1994; 107:747–754.
301. Hunt RH. Review article: the unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther 2005; 22(Suppl 3):S10–S19.
302. Metz DC, Inadomi JM, Howden CW, et al
. On-demand therapy for gastroesophageal reflux disease. Am J Gastroenterol 2007; 102:642–653.
303. Metz DC, Howden CW, Perez MC, Larsen L, et al
. Clinical Trial. Dexlansoprazole MR, a proton pump inhibitor with Dual Delayed Release technology, effectively controls symptoms and prevents relapse in patients with healed erosive esophagitis. Aliment Pharmacol Ther 2009; 29:742–754.
304. Andersson T, Hassall E, Lundborg P, et al
. Pharmacokinetics of orally administered omeprazole in children. International Pediatric Omeprazole Pharmacokinetic Group. Am J Gastroenterol 2000; 95:3101–3106.
305. Litalien C, Théorêt Y, Faure C. Pharmacokinetics of proton pump inhibitors in children. Clin Pharmacokinet 2005; 44:441–466.
306. Zhao J, Li J, Hamer-Maansson JE, et al
. Pharmacokinetic properties of esomeprazole in children aged 1 to 11 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006; 28:1868–1876.
307. Gremse D, Winter H, Tolia V, et al
. Pharmacokinetics and pharmacodynamics of lansoprazole in children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2002; 35(Suppl 4):S319–S326.
308. Omari TI, Haslam RR, Lundborg P, et al
. Effect of omeprazole on acid gastroesophageal reflux and gastric acidity in preterm infants with pathological acid reflux. J Pediatr Gastroenterol Nutr 2007; 44:41–44.
309. Zhang W, Kukulka M, Witt G, et al
. Age-dependent pharmacokinetics of lansoprazole in neonates and infants. Paediatr Drugs 2008; 10:265–274.
310. Hassall E. Talk is cheap, often effective: symptoms in infants often respond to non-pharmacologic measures. J Pediatr 2008; 152:301–303.
311. Li J, Zhao J, Hamer-Maansson JE, et al
. Pharmacokinetic properties of esomeprazole in adolescent patients aged 12 to 17 years with symptoms of gastroesophageal reflux disease: a randomized, open-label study. Clin Ther 2006; 28:419–427.
312. Tolia V, Fitzgerald J, Hassall E, et al
. Safety of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35(Suppl 4):S300–S307.
313. Drut R, Altamirano E, Cueto Rua E. Omeprazole-associated changes in the gastric mucosa of children. J Clin Pathol
314. Hassall E, Dimmick JE, Israel DM. Parietal cell hyperplasia in children receiving omeprazole. Gastroenterology 1995; 108:A110.
315. Pashankar DS, Israel DM. Gastric polyps and nodules in children receiving long-term omeprazole therapy. J Pediatr Gastroenterol Nutr 2002; 35:658–662.
316. Hassall E, for the International Pediatric Omeprazole Study Group. Omeprazole for maintenance therapy of erosive esophagitis in children. Gastroenterology 2000; 118:A658.
317. Hassall E, Owen D, Kerr W, et al
. Gastric histology in children treated with proton pump inhibitors (PPIs) long-term. Gastroenterology 2008; 134:A174.
318. Canani RB, Cirillo P, Roggero P, et al
. Therapy with gastric acidity inhibitors increases the risk of acute gastroenteritis and community-acquired pneumonia in children. Pediatrics 2006; 117:e817–e820.
319. Guillet R, Stoll BJ, Cotten CM, et al
. Association of H2
-blocker therapy and higher incidence of necrotizing enterocolitis in very low birth weight infants. Pediatrics 2006; 117:e137–e142.
320. Saiman L, Ludington E, Dawson JD, et al
. Risk factors for Candida species colonization of neonatal intensive care unit patients. Pediatr Infect Dis J 2001; 20:1119–1124.
321. Dial S, Delaney JA, Barkun AN, et al
. Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease. JAMA 2005; 294:2989–2995.
322. Laheij RJ, Sturkenboom MC, Hassing RJ, et al
. Risk of community-acquired pneumonia and use of gastric acid-suppressive drugs. JAMA 2004; 292:1955–1960.
323. Garcia Rodriguez LA, Ruigomez A, Panes J. Use of acid-suppressing drugs and the risk of bacterial gastroenteritis. Clin Gastroenterol Hepatol 2007; 5:1418–1423.
324. Williams C, McColl KE. Review article: proton pump inhibitors and bacterial overgrowth. Aliment Pharmacol Ther 2006; 23:3–10.
325. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol 2004; 57:422–428.
326. Yang YX, Lewis JD, Epstein S, et al
. Long-term proton pump inhibitor therapy and risk of hip fracture. JAMA 2006; 296:2947–2953.
327. den Elzen WP, Groeneveld Y, de Ruijter W, et al
. Long-term use of proton pump inhibitors and vitamin B12 status in elderly individuals. Aliment Pharmacol Ther 2008; 27:491–497.
328. Kaye JA, Jick H. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors. Pharmacotherapy 2008; 28:951–959.
329. Geevasinga N, Coleman PL, Webster AC, et al
. Proton pump inhibitors and acute interstitial nephritis. Clin Gastroenterol Hepatol 2006; 4:597–604.
330. Brewster UC, Perazella MA. Proton pump inhibitors and the kidney: critical review. Clin Nephrol 2007; 68:65–72.
331. Untersmayr E, Jensen-Jarolim E. The role of protein digestibility and antacids on food allergy outcomes. J Allergy Clin Immunol 2008; 121:1301–1308, quiz 1309–10.
332. Rode H, Stunden RJ, Millar AJ, et al
. Esophageal pH assessment of gastroesophageal reflux in 18 patients and the effect of two prokinetic agents: cisapride and metoclopramide. J Pediatr Surg 1987; 22:931–934.
333. Augood C, MacLennan S, Gilbert R, Logan S. Cisapride treatment for gastro-oesophageal reflux in children. Cochrane Database Syst Rev
334. Dalby-Payne JR, Morris AM, Craig JC. Meta-analysis of randomized controlled trials on the benefits and risks of using cisapride for the treatment of gastroesophageal reflux in children. J Gastroenterol Hepatol 2003; 18:196–202.
335. Perrio M, Voss S, Shakir SA. Application of the bradford hill criteria to assess the causality of cisapride-induced arrhythmia: a model for assessing causal association in pharmacovigilance. Drug Saf 2007; 30:333–346.
336. Tolia V, Calhoun J, Kuhns L, et al
. Randomized, prospective double-blind trial of metoclopramide and placebo for gastroesophageal reflux in infants. J Pediatr 1989; 115:141–145.
337. Machida HM, Forbes DA, Gall DG, et al
. Metoclopramide in gastroesophageal reflux of infancy. J Pediatr 1988; 112:483–487.
338. Shafrir Y, Levy Y, Beharab A, et al
. Acute dystonic reaction to bethanechol–a direct acetylcholine receptor agonist. Dev Med Child Neurol 1986; 28:646–648.
339. Madani S, Tolia V. Gynecomastia with metoclopramide use in pediatric patients. J Clin Gastroenterol 1997; 24:79–81.
340. Putnam PE, Orenstein SR, Wessel HB, et al
. Tardive dyskinesia associated with use of metoclopramide in a child. J Pediatr 1992; 121:983–985.
341. Pritchard DS, Baber N, Stephenson T. Should domperidone be used for the treatment of gastro-oesophageal reflux in children? Systematic review of randomized controlled trials in children aged 1 month to 11 years old. Br J Clin Pharmacol 2005; 59:725–729.
342. Djeddi D, Kongolo G, Lefaix C, et al
. Effect of domperidone on QT interval in neonates. J Pediatr 2008; 153:663–666.
343. Euler AR. Use of bethanechol for the treatment of gastroesophageal reflux. J Pediatr 1980; 96:321–324.
344. Levi P, Marmo F, Saluzzo C, et al
. Bethanechol versus antiacids in the treatment of gastroesophageal reflux. Helv Paediatr Acta 1985; 40:349–359.
345. Vela MF, Tutuian R, Katz PO, et al
. Baclofen decreases acid and non-acid post-prandial gastro-oesophageal reflux measured by combined multichannel intraluminal impedance and pH. Aliment Pharmacol Ther 2003; 17:243–251.
346. Omari TI, Benninga MA, Sansom L, et al
. Effect of baclofen on esophagogastric motility and gastroesophageal reflux in children with gastroesophageal reflux disease: a randomized controlled trial. J Pediatr 2006; 149:468–474.
347. Kawai M, Kawahara H, Hirayama S, et al
. Effect of baclofen on emesis and 24-hour esophageal pH in neurologically impaired children with gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2004; 38:317–323.
348. Di Lorenzo C. Gastroesophageal reflux: not a time to “relax”. J Pediatr 2006; 149:436–438.
349. Rocha CM, Barbosa MM. QT interval prolongation associated with the oral use of domperidone in an infant. Pediatr Cardiol 2005; 26:720–723.
350. Hibbs AM, Lorch SA. Metoclopramide for the treatment of gastroesophageal reflux disease in infants: a systematic review. Pediatrics 2006; 118:746–752.
351. Tran TT, Quandalle P. Long term results of treatment by simple surgical closure of perforated gastroduodenal ulcer followed by eradication of Helicobacter pylori. Ann Chir 2006; 131:502–503.
352. Cucchiara S, Staiano A, Romaniello G, et al
. Antacids and cimetidine treatment for gastro-oesophageal reflux and peptic oesophagitis. Arch Dis Child 1984; 59:842–847.
353. Iacono G, Carroccio A, Montalto G, et al
. Magnesium hydroxide and aluminum hydroxide in the treatment of gastroesophageal reflux. Minerva Pediatr 1991; 43:797–800.
354. Tsou VM, Young RM, Hart MH, et al
. Elevated plasma aluminum levels in normal infants receiving antacids containing aluminum. Pediatrics 1991; 87:148–151.
355. Woodard-Knight L, Fudge A, Teubner J, et al
. Aluminium absorption and antacid therapy in infancy. J Paediatr Child Health 1992; 28:257–259.
356. Sedman A. Aluminum toxicity in childhood. Pediatr Nephrol 1992; 6:383–393.
357. American Academy of Pediatrics Committee on Nutrition. Aluminum toxicity in infants and children. Pediatrics
358. Friedman JA, Carroll JC, Bergstrom WH. Antacid-induced hypophosphatemic rickets. Drug Nutr Interact 1985; 3:197–199.
359. Beall DP, Henslee HB, Webb HR, et al
. Milk-alkali syndrome: a historical review and description of the modern version of the syndrome. Am J Med Sci 2006; 331:233–242.
360. Greally P, Hampton FJ, MacFadyen UM, et al
. Gaviscon and Carobel compared with cisapride in gastro-oesophageal reflux. Arch Dis Child 1992; 67:618–621.
361. Forbes D, Hodgson M, Hill R. The effects of gaviscon and metoclopramide in gastroesophageal reflux in children. J Pediatr Gastroenterol Nutr 1986; 5:556–559.
362. Le Luyer B, Mougenot JF, Mashako L, et al
. Multicenter study of sodium alginate in the treatment of regurgitation in infants. Ann Pediatr (Paris) 1992; 39:635–640.
363. Buts JP, Barudi C, Otte JB. Double-blind controlled study on the efficacy of sodium alginate (Gaviscon) in reducing gastroesophageal reflux assessed by 24 h continuous pH monitoring in infants and children. Eur J Pediatr 1987; 146:156–158.
364. Miller S. Comparison of the efficacy and safety of a new aluminium-free paediatric alginate preparation and placebo in infants with recurrent gastro-oesophageal reflux. Curr Med Res Opin 1999; 15:160–168.
365. Del Buono R, Wenzl TG, Ball G, et al
. Effect of Gaviscon Infant on gastro-oesophageal reflux in infants assessed by combined intraluminal impedance/pH. Arch Dis Child 2005; 90:460–463.
366. Simon B, Ravelli GP, Goffin H. Sucralfate gel versus placebo in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1996; 10:441–446.
367. Arguelles-Martin F, Gonzalez-Fernandez F, Gentles MG. Sucralfate versus cimetidine in the treatment of reflux esophagitis in children. Am J Med 1989; 86:73–76.
368. Lobe TE. The current role of laparoscopic surgery for gastroesophageal reflux disease in infants and children. Surg Endosc 2007; 21:167–174.
369. Berquist WE, Fonkalsrud EW, Ament ME. Effectiveness of Nissen fundoplication for gastroesophageal reflux in children as measured by 24-hour intraesophageal pH monitoring. J Pediatr Surg 1981; 16:872–875.
370. Di Lorenzo C, Flores A, Hyman PE. Intestinal motility in symptomatic children with fundoplication. J Pediatr Gastroenterol Nutr 1991; 12:169–173.
371. Di Lorenzo C, Orenstein S. Fundoplication: friend or foe? J Pediatr Gastroenterol Nutr 2002; 34:117–124.
372. Hassall E. Outcomes of fundoplication: causes for concern, newer options. Arch Dis Child 2005; 90:1047–1052.
373. Kawahara H, Nakajima K, Yagi M, et al
. Mechanisms responsible for recurrent gastroesophageal reflux in neurologically impaired children who underwent laparoscopic Nissen fundoplication. Surg Endosc 2002; 16:767–771.
374. Gilger MA, Yeh C, Chiang J, et al
. Outcomes of surgical fundoplication in children. Clin Gastroenterol Hepatol 2004; 2:978–984.
375. Gibbons TE, Stockwell JA, Kreh RP, et al
. Population-based epidemiological survey of gastroesophageal reflux disease in hospitalized US children. Gastroenterology 2001; 120:A419.
376. Fonkalsrud EW, Ashcraft KW, Coran AG, et al
. Surgical treatment of gastroesophageal reflux in children: a combined hospital study of 7467 patients. Pediatrics 1998; 101:419–422.
377. Mathei J, Coosemans W, Nafteux P, et al
. Laparoscopic Nissen fundoplication in infants and children: analysis of 106 consecutive patients with special emphasis in neurologically impaired vs. neurologically normal patients. Surg Endosc 2008; 22:1054–1059.
378. Vakil N. Review article: the role of surgery in gastro-oesophageal reflux disease. Aliment Pharmacol Ther 2007; 25:1365–1372.
379. Vakil N, Shaw M, Kirby R. Clinical effectiveness of laparoscopic fundoplication in a U.S. community. Am J Med 2003; 114:1–5.
380. Jackson PG, Gleiber MA, Askari R, et al
. Predictors of outcome in 100 consecutive laparoscopic antireflux procedures. Am J Surg 2001; 181:231–235.
381. Spechler SJ, Lee E, Ahnen D, et al
. Long-term outcome of medical and surgical therapies for gastroesophageal reflux disease: follow-up of a randomized controlled trial. JAMA 2001; 285:2331–2338.
382. Wijnhoven BP, Lally CJ, Kelly JJ, et al
. Use of antireflux medication after antireflux surgery. J Gastrointest Surg 2008; 12:510–517.
383. Sullivan EM, Pelletier EM, Richter JE. Use of acid reduction therapy and medical costs among medically vs surgically managed GERD patients. Am J Gastroenterol 2002; 97:S239.
384. Lundell L, Attwood S, Ell C, et al
. Comparing laparoscopic antireflux surgery with esomeprazole in the management of patients with chronic gastro-oesophageal reflux disease: a 3-year interim analysis of the LOTUS trial. Gut 2008; 57:1207–1213.
385. Lundell L. Complications after anti-reflux surgery. Best Pract Res Clin Gastroenterol 2004; 18:935–945.
386. Perdikis G, Hinder RA, Lund RJ, et al
. Laparoscopic Nissen fundoplication: where do we stand? Surg Laparosc Endosc 1997; 7:17–21.
387. Rantanen TK, Salo JA, Sipponen JT. Fatal and life-threatening complications in antireflux surgery: analysis of 5,502 operations. Br J Surg 1999; 86:1573–1577.
388. Pearl RH, Robie DK, Ein SH, et al
. Complications of gastroesophageal antireflux surgery in neurologically impaired versus neurologically normal children. J Pediatr Surg 1990; 25:1169–1173.
389. Smith CD, Othersen HB Jr, Gogan NJ, et al
. Nissen fundoplication in children with profound neurologic disability. High risks and unmet goals. Ann Surg 1992; 215:654–658, discussion 658–9.
390. Spitz L, Roth K, Kiely EM, et al
. Operation for gastro-oesophageal reflux associated with severe mental retardation. Arch Dis Child 1993; 68:347–351.
391. Martinez DA, Ginn-Pease ME, Caniano DA. Recognition of recurrent gastroesophageal reflux following antireflux surgery in the neurologically disabled child: high index of suspicion and definitive evaluation. J Pediatr Surg 1992; 27:983–988, discussion 988–90.
392. Martinez DA, Ginn-Pease ME, Caniano DA. Sequelae of antireflux surgery in profoundly disabled children. J Pediatr Surg 1992; 27:267–271, discussion 271–3.
393. Curci MR, Dibbins AW. Problems associated with a Nissen fundoplication following tracheoesophageal fistula and esophageal atresia repair. Arch Surg 1988; 123:618–620.
394. Wheatley MJ, Coran AG, Wesley JR. Efficacy of the Nissen fundoplication in the management of gastroesophageal reflux following esophageal atresia repair. J Pediatr Surg 1993; 28:53–55.
395. Diaz DM, Gibbons TE, Heiss K, et al
. Antireflux surgery outcomes in pediatric gastroesophageal reflux disease. Am J Gastroenterol 2005; 100:1844–1852.
396. Kubiak R, Spitz L, Kiely EM, et al
. Effectiveness of fundoplication in early infancy. J Pediatr Surg 1999; 34:295–299.
397. Goldin AB, Sawin R, Seidel KD, et al
. Do antireflux operations decrease the rate of reflux-related hospitalizations in children? Pediatrics 2006; 118:2326–2333.
398. Lee SL, Shabatian H, Hsu JW, et al
. Hospital admissions for respiratory symptoms and failure to thrive before and after Nissen fundoplication. J Pediatr Surg 2008; 43:59–63, discussion 63–5.
399. Harnsberger JK, Corey JJ, Johnson DG, et al
. Long-term follow-up of surgery for gastroesophageal reflux in infants and children. J Pediatr 1983; 102:505–508.
400. Caniano DA, Ginn-Pease ME, King DR. The failed antireflux procedure: analysis of risk factors and morbidity. J Pediatr Surg 1990; 25:1022–1025, discussion 1025–6.
401. Carlson MA, Frantzides CT. Complications and results of primary minimally invasive antireflux procedures: a review of 10,735 reported cases. J Am Coll Surg 2001; 193:428–439.
402. Dalla Vecchia LK, Grosfeld JL, West KW, et al
. Reoperation after Nissen fundoplication in children with gastroesophageal reflux: experience with 130 patients. Ann Surg 1997; 226:315–321, discussion 321–3.
403. Lindahl H, Rintala R, Louhimo I. Failure of the Nissen fundoplication to control gastroesophageal reflux in esophageal atresia patients. J Pediatr Surg 1989; 24:985–987.
404. Taylor LA, Weiner T, Lacey SR, et al
. Chronic lung disease is the leading risk factor correlating with the failure (wrap disruption) of antireflux procedures in children. J Pediatr Surg 1994; 29:161–164, discussion 164–6.
405. van der Zee DC, Arends NJ, Bax NM. The value of 24-h pH study in evaluating the results of laparoscopic antireflux surgery in children. Surg Endosc 1999; 13:918–921.
406. Lasser MS, Liao JG, Burd RS. National trends in the use of antireflux procedures for children. Pediatrics 2006; 118:1828–1835.
407. Capito C, Leclair MD, Piloquet H, et al
. Long-term outcome of laparoscopic Nissen-Rossetti fundoplication for neurologically impaired and normal children. Surg Endosc 2008; 22:875–880.
408. Luostarinen ME, Isolauri JO. Surgical experience improves the long-term results of Nissen fundoplication. Scand J Gastroenterol 1999; 34:117–120.
409. Watson DI, Baigrie RJ, Jamieson GG. A learning curve for laparoscopic fundoplication. Definable, avoidable, or a waste of time? Ann Surg 1996; 224:198–203.
410. Bais JE, Bartelsman JF, Bonjer HJ, et al
. Laparoscopic or conventional Nissen fundoplication for gastro-oesophageal reflux disease: randomised clinical trial. The Netherlands Antireflux Surgery Study Group. Lancet 2000; 355:170–174.
411. Lall A, Morabito A, Dall'Oglio L, et al
. Total oesophagogastric dissociation: experience in 2 centres. J Pediatr Surg 2006; 41:342–346.
412. Morabito A, Lall A, Lo Piccolo R, et al
. Total esophagogastric dissociation: 10 years' review. J Pediatr Surg 2006; 41:919–922.
413. Thomson M, Antao B, Hall S, et al
. Medium-term outcome of endoluminal gastroplication with the EndoCinch device in children. J Pediatr Gastroenterol Nutr 2008; 46:172–177.
414. Pace F, Costamagna G, Penagini R, et al
. Review article: endoscopic antireflux procedures - an unfulfilled promise? Aliment Pharmacol Ther 2008; 27:375–384.
415. Rothstein RI. Endoscopic therapy of gastroesophageal reflux disease: outcomes of the randomized-controlled trials done to date. J Clin Gastroenterol 2008; 42:594–602.
416. Hogan WJ. Clinical trials evaluating endoscopic GERD treatments: is it time for a moratorium on the clinical use of these procedures? Am J Gastroenterol 2006; 101:437–439.
417. Corley DA, Katz P, Wo JM, et al
. Improvement of gastroesophageal reflux symptoms after radiofrequency energy: a randomized, sham-controlled trial. Gastroenterology 2003; 125:668–676.
418. Wang SC, Borison HL. A new concept of organization of the central emetic mechanism: recent studies on the sites of action of apomorphine, copper sulfate and cardiac glycosides. Gastroenterology 1952; 22:1–12.
419. Orenstein SR, Peters JM. Vomiting and regurgitation. In: Kleigman RM, Greenbaum LA, Lye PS, editors. Practical Strategies in Pediatric Diagnosis and Therapy. 2nd ed. Philadelphia: WB Saunders Company; 2004.
420. Shalaby TM, Orenstein SR. Efficacy of telephone teaching of conservative therapy for infants with symptomatic gastroesophageal reflux referred by pediatricians to pediatric gastroenterologists. J Pediatr 2003; 142:57–61.
421. Cavataio F, Carroccio A, Iacono G. Milk-induced reflux in infants less than one year of age. J Pediatr Gastroenterol Nutr 2000; 30(Suppl):S36–S44.
422. Reijneveld SA, Lanting CI, Crone MR, et al
. Exposure to tobacco smoke and infant crying. Acta Paediatr 2005; 94:217–221.
423. Shenassa ED, Brown MJ. Maternal smoking and infantile gastrointestinal dysregulation: the case of colic. Pediatrics 2004; 114:e497–e505.
424. Hunziker UA, Barr RG. Increased carrying reduces infant crying: a randomized controlled trial. Pediatrics 1986; 77:641–648.
425. Barr RG. The normal crying curve: what do we really know? Dev Med Child Neurol 1990; 32:356–362.
426. Armstrong KL, Quinn RA, Dadds MR. The sleep patterns of normal children. Med J Aust 1994; 161:202–206.
427. Singh S, Richter JE, Bradley LA, et al
. The symptom index. Differential usefulness in suspected acid-related complaints of heartburn and chest pain. Dig Dis Sci 1993; 38:1402–1408.
428. Richter JE. A critical review of current medical therapy for gastroesophageal reflux disease. J Clin Gastroenterol 1986; 8(Suppl 1):S72–80.
429. Vakil N. Proton pump inhibitors for dyspepsia. Dig Dis 2008; 26:215–217.
430. Feranchak AP, Orenstein SR, Cohn JF. Behaviors associated with onset of gastroesophageal reflux episodes in infants. Prospective study using split-screen video and pH probe. Clin Pediatr (Phila) 1994; 33:654–662.
431. Heine RG, Jaquiery A, Lubitz L, et al
. Role of gastro-oesophageal reflux in infant irritability. Arch Dis Child 1995; 73:121–125.
432. Ghaem M, Armstrong KL, Trocki O, et al
. The sleep patterns of infants and young children with gastro-oesophageal reflux. J Paediatr Child Health 1998; 34:160–163.
433. Arana A, Bagucka B, Hauser B, et al
. pH monitoring in the distal and proximal esophagus in symptomatic infants. J Pediatr Gastroenterol Nutr 2001; 32:259–264.
434. Barr RG, Rotman A, Yaremko J, et al
. The crying of infants with colic: a controlled empirical description. Pediatrics 1992; 90:14–21.
435. Zwart P, Vellema-Goud MG, Brand PL. Characteristics of infants admitted to hospital for persistent colic, and comparison with healthy infants. Acta Paediatr 2007; 96:401–405.
436. Vandenplas Y, Koletzko S, Isolauri E, et al
. Guidelines for the diagnosis and management of cow's milk protein allergy in infants. Arch Dis Child 2007; 92:902–908.
437. Rao MR, Brenner RA, Schisterman EF, et al
. Long term cognitive development in children with prolonged crying. Arch Dis Child 2004; 89:989–992.
438. Poole SR. The infant with acute, unexplained, excessive crying. Pediatrics 1991; 88:450–455.
439. Barr RG. Colic and crying syndromes in infants. Pediatrics 1998; 102:1282–1286.
440. Savino F, Palumeri E, Castagno E, et al
. Reduction of crying episodes owing to infantile colic: a randomized controlled study on the efficacy of a new infant formula. Eur J Clin Nutr 2006; 60:1304–1310.
441. Lucassen PL, Assendelft WJ, Gubbels JW, et al
. Infantile colic: crying time reduction with a whey hydrolysate: a double-blind, randomized, placebo-controlled trial. Pediatrics 2000; 106:1349–1354.
442. Hill DJ, Hudson IL, Sheffield LJ, et al
. A low allergen diet is a significant intervention in infantile colic: results of a community-based study. J Allergy Clin Immunol 1995; 96:886–892.
443. Klauser AG, Schindlbeck NE, Muller-Lissner SA. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335:205–208.
444. Shi G, Bruley des Varannes S, Scarpignato C, et al
. Reflux related symptoms in patients with normal oesophageal exposure to acid. Gut 1995; 37:457–464.
445. Dent J, Brun J, Fendrick AM, et al
. An evidence-based appraisal of reflux disease management - the Genval workshop report. Gut 1999; 44(Suppl 2):S1–S16.
446. Venables TL, Newland RD, Patel AC, et al
. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32:965–973.
447. Fiedorek S, Tolia V, Gold BD, et al
. Efficacy and safety of lansoprazole in adolescents with symptomatic erosive and non-erosive gastroesophageal reflux disease. J Pediatr Gastroenterol Nutr 2005; 40:319–327.
448. Richter JE, Kovacs TO, Greski-Rose PA, et al
. Lansoprazole in the treatment of heartburn in patients without erosive oesophagitis. Aliment Pharmacol Ther 1999; 13:795–804.
449. DeVault KR, Castell DO. Updated guidelines for the diagnosis and treatment of gastroesophageal reflux disease. The Practice Parameters Committee of the American College of Gastroenterology. Am J Gastroenterol 1999; 94:1434–1442.
450. Muller S, Puhl S, Vieth M, et al
. Analysis of symptoms and endoscopic findings in 117 patients with histological diagnoses of eosinophilic esophagitis. Endoscopy 2007; 39:339–344.
451. Fossmark R, Johnsen G, Johanessen E, et al
. Rebound acid hypersecretion after long-term inhibition of gastric acid secretion. Aliment Pharmacol Ther 2005; 21:149–154.
452. Bjornsson E, Abrahamsson H, Simren M, et al
. Discontinuation of proton pump inhibitors in patients on long-term therapy: a double-blind, placebo-controlled trial. Aliment Pharmacol Ther 2006; 24:945–954.
453. Havelund T, Lind T, Wiklund I, et al
. Quality of life in patients with heartburn but without esophagitis: effects of treatment with omeprazole. Am J Gastroenterol 1999; 94:1782–1789.
454. Revicki DA, Crawley JA, Zodet MW, et al
. Complete resolution of heartburn symptoms and health-related quality of life in patients with gastro-oesophageal reflux disease. Aliment Pharmacol Ther 1999; 13:1621–1630.
455. Pappa KA, Williams BO, Payne JE, et al
. A double-blind, placebo-controlled study of the efficacy and safety of non-prescription ranitidine 75 mg in the prevention of meal-induced heartburn. Aliment Pharmacol Ther 1999; 13:467–473.
456. Pace F, Tonini M, Pallotta S, et al
. Systematic review: maintenance treatment of gastro-oesophageal reflux disease with proton pump inhibitors taken ‘on-demand’. Aliment Pharmacol Ther 2007; 26:195–204.
457. DeVault KR. Review article: the role of acid suppression in patients with non-erosive reflux disease or functional heartburn. Aliment Pharmacol Ther 2006; 23(Suppl 1):33–39.
458. Fass R. Erosive esophagitis and nonerosive reflux disease (NERD): comparison of epidemiologic, physiologic, and therapeutic characteristics. J Clin Gastroenterol 2007; 41:131–137.
459. Tolia V, Ferry G, Gunasekaran T, et al
. Efficacy of lansoprazole in the treatment of gastroesophageal reflux disease in children. J Pediatr Gastroenterol Nutr 2002; 35:S308–S318.
460. Wang KK, Sampliner RE. Updated guidelines 2008 for the diagnosis, surveillance and therapy of Barrett's esophagus. Am J Gastroenterol 2008; 103:788–797.
461. Sharma P, McQuaid K, Dent J, et al
. A critical review of the diagnosis and management of Barrett's esophagus: the AGA Chicago Workshop. Gastroenterology 2004; 127:310–330.
462. Eslick GD, Talley NJ. Dysphagia: epidemiology, risk factors and impact on quality of life–a population-based study. Aliment Pharmacol Ther 2008; 27:971–979.
463. Bollschweiler E, Knoppe K, Wolfgarten E, et al
. Prevalence of Dysphagia in patients with gastroesophageal reflux in Germany. Dysphagia 2008; 23:172–176.
464. Vakil NB, Traxler B, Levine D. Dysphagia in patients with erosive esophagitis: prevalence, severity, and response to proton pump inhibitor treatment. Clin Gastroenterol Hepatol 2004; 2:665–668.
465. Lundquist A, Olsson R, Ekberg O. Clinical and radiologic evaluation reveals high prevalence of abnormalities in young adults with dysphagia. Dysphagia 1998; 13:202–207.
466. Pasha SF, DiBaise JK, Kim HJ, et al
. Patient characteristics, clinical, endoscopic, and histologic findings in adult eosinophilic esophagitis: a case series and systematic review of the medical literature. Dis Esophagus 2007; 20:311–319.
467. Dellert SF, Hyams JS, Treem WR, et al
. Feeding resistance and gastroesophageal reflux in infancy. J Pediatr Gastroenterol Nutr 1993; 17:66–71.
468. Mathisen B, Worrall L, Masel J, et al
. Feeding problems in infants with gastro-oesophageal reflux disease: a controlled study. J Paediatr Child Health 1999; 35:163–169.
469. Rommel N, De Meyer AM, Feenstra L, et al
. The complexity of feeding problems in 700 infants and young children presenting to a tertiary care institution. J Pediatr Gastroenterol Nutr 2003; 37:75–84.
470. Mousa H, Woodley FW, Metheney M, et al
. Testing the association between gastroesophageal reflux and apnea in infants. J Pediatr Gastroenterol Nutr 2005; 41:169–177.
471. Peter CS, Sprodowski N, Bohnhorst B, et al
. Gastroesophageal reflux and apnea of prematurity: no temporal relationship. Pediatrics 2002; 109:8–11.
472. Magista AM, Indrio F, Baldassarre M, et al
. Multichannel intraluminal impedance to detect relationship between gastroesophageal reflux and apnoea of prematurity. Dig Liver Dis 2007; 39:216–221.
473. Menon AP, Schefft GL, Thach BT. Apnea associated with regurgitation in infants. J Pediatr 1985; 106:625–629.
474. National Institutes of Health Consensus Development Conference. Infantile apnea and home monitoring: consensus statement. Pediatrics
475. Tirosh E, Kessel A, Jaffe M, et al
. Outcome of idiopathic apparent life-threatening events: infant and mother perspectives. Pediatr Pulmonol 1999; 28:47–52.
476. Cote A, Hum C, Brouillette RT, et al
. Frequency and timing of recurrent events in infants using home cardiorespiratory monitors. J Pediatr 1998; 132:783–789.
477. Rosen CL, Frost JD Jr, Harrison GM. Infant apnea: polygraphic studies and follow-up monitoring. Pediatrics 1983; 71:731–736.
478. Burchfield DJ, Rawlings DJ. Sudden deaths and apparent life-threatening events in hospitalized neonates presumed to be healthy. Am J Dis Child 1991; 145:1319–1322.
479. Kahn A, Blum D, Rebuffat E, et al
. Polysomnographic studies of infants who subsequently died of sudden infant death syndrome. Pediatrics 1988; 82:721–727.
480. Kelly DH, Golub H, Carley D, et al
. Pneumograms in infants who subsequently died of sudden infant death syndrome. J Pediatr 1986; 109:249–254.
481. Kelly DH, Shannon DC, O'Connell K. Care of infants with near-miss sudden infant death syndrome. Pediatrics 1978; 61:511–514.
482. Oren J, Kelly D, Shannon DC. Identification of a high-risk group for sudden infant death syndrome among infants who were resuscitated for sleep apnea. Pediatrics 1986; 77:495–499.
483. Friesen CA, Streed CJ, Carney LA, et al
. Esophagitis and modified Bernstein tests in infants with apparent life-threatening events. Pediatrics 1994; 94:541–544.
484. Newman LJ, Russe J, Glassman MS, et al
. Patterns of gastroesophageal reflux (GER) in patients with apparent life-threatening events. J Pediatr Gastroenterol Nutr 1989; 8:157–160.
485. Herbst JJ, Minton SD, Book LS. Gastroesophageal reflux causing respiratory distress and apnea in newborn infants. J Pediatr 1979; 95:763–768.
486. Leape LL, Holder TM, Franklin JD, et al
. Respiratory arrest in infants secondary to gastroesophageal reflux. Pediatrics 1977; 60:924–928.
487. Herbst JJ, Book LS, Bray PF. Gastroesophageal reflux in the “near miss” sudden infant death syndrome. J Pediatr 1978; 92:73–75.
488. Spitzer AR, Boyle JT, Tuchman DN, et al
. Awake apnea associated with gastroesophageal reflux: a specific clinical syndrome. J Pediatr 1984; 104:200–205.
489. Ariagno RL. Evaluation and management of infantile apnea. Pediatr Ann 1984; 13:210–213, 216–217.
490. Kahn A, Rebuffat E, Sottiaux M, et al
. Lack of temporal relation between acid reflux in the proximal oesophagus and cardiorespiratory events in sleeping infants. Eur J Pediatr 1992; 151:208–212.
491. Veereman-Wauters G, Bochner A, Van Caillie-Bertrand M. Gastroesophageal reflux in infants with a history of near-miss sudden infant death. J Pediatr Gastroenterol Nutr 1991; 12:319–323.
492. Sacre L, Vandenplas Y. Gastroesophageal reflux associated with respiratory abnormalities during sleep. J Pediatr Gastroenterol Nutr 1989; 9:28–33.
493. Paton JY, Nanayakkara CS, Simpson H. Observations on gastro-oesophageal reflux, central apnoea and heart rate in infants. Eur J Pediatr 1990; 149:608–612.
494. Paton JY, Macfadyen U, Williams A, et al
. Gastro-oesophageal reflux and apnoeic pauses during sleep in infancy - no direct relation. Eur J Pediatr 1990; 149:680–686.
495. Walsh JK, Farrell MK, Keenan WJ, et al
. Gastroesophageal reflux in infants: relation to apnea. J Pediatr 1981; 99:197–201.
496. Suys B, De Wolf D, Hauser B, et al
. Bradycardia and gastroesophageal reflux in term and preterm infants: is there any relation? J Pediatr Gastroenterol Nutr 1994; 19:187–190.
497. Jolley SG, Halpern LM, Tunell WP, et al
. The risk of sudden infant death from gastroesophageal reflux. J Pediatr Surg 1991; 26:691–696.
498. Field SK. A critical review of the studies of the effects of simulated or real gastroesophageal reflux on pulmonary function in asthmatic adults. Chest 1999; 115:848–856.
499. Boyle JT, Tuchman DN, Altschuler SM, et al
. Mechanisms for the association of gastroesophageal reflux and bronchospasm. Am Rev Respir Dis 1985; 131:S16–S20.
500. Malfroot A, Dab I. Pathophysiology and mechanisms of gastroesophageal reflux in childhood asthma. Pediatr Pulmonol Suppl 1995; 11:55–56.
501. Hamamoto J, Kohrogi H, Kawano O, et al
. Esophageal stimulation by hydrochloric acid causes neurogenic inflammation in the airways in guinea pigs. J Appl Physiol 1997; 82:738–745.
502. Herve P, Denjean A, Jian R, et al
. Intraesophageal perfusion of acid increases the bronchomotor response to methacholine and to isocapnic hyperventilation in asthmatic subjects. Am Rev Respir Dis 1986; 134:986–989.
503. Sontag SJ, O'Connell S, Khandelwal S, et al
. Most asthmatics have gastroesophageal reflux with or without bronchodilator therapy. Gastroenterology 1990; 99:613–620.
504. Lazenby JP, Guzzo MR, Harding SM, et al
. Oral corticosteroids increase esophageal acid contact times in patients with stable asthma. Chest 2002; 121:625–634.
505. Scarupa MD, Mori N, Canning BJ. Gastroesophageal reflux disease in children with asthma: treatment implications. Paediatr Drugs 2005; 7:177–186.
506. Sheikh S, Stephen T, Howell L, et al
. Gastroesophageal reflux in infants with wheezing. Pediatr Pulmonol 1999; 28:181–186.
507. Condino AA, Sondheimer J, Pan Z, et al
. Evaluation of gastroesophageal reflux in pediatric patients with asthma using impedance-pH monitoring. J Pediatr 2006; 149:216–219.
508. Stordal K, Johannesdottir GB, Bentsen BS, et al
. Acid suppression does not change respiratory symptoms in children with asthma and gastro-oesophageal reflux disease. Arch Dis Child 2005; 90:956–960.
509. Kiljander TO, Harding SM, Field SK, et al
. Effects of esomeprazole 40 mg twice daily on asthma: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2006; 173:1091–1097.
510. Littner MR, Leung FW, Ballard ED 2nd, et al
. Effects of 24 weeks of lansoprazole therapy on asthma symptoms, exacerbations, quality of life, and pulmonary function in adult asthmatic patients with acid reflux symptoms. Chest 2005; 128:1128–1135.
511. Khoshoo V, Le T, Haydel RM Jr, et al
. Role of gastroesophageal reflux in older children with persistent asthma. Chest 2003; 123:1008–1013.
512. Sontag SJ, O'Connell S, Khandelwal S, et al
. Asthmatics with gastroesophageal reflux: long term results of a randomized trial of medical and surgical antireflux therapies. Am J Gastroenterol 2003; 98:987–999.
513. Boesch RP, Daines C, Willging JP, et al
. Advances in the diagnosis and management of chronic pulmonary aspiration in children. Eur Respir J 2006; 28:847–861.
514. Euler AR, Byrne WJ, Ament ME, et al
. Recurrent pulmonary disease in children: a complication of gastroesophageal reflux. Pediatrics 1979; 63:47–51.
515. Carre IJ. Pulmonary infections in children with a partial thoracic stomach (‘hiatus hernia’). Arch Dis Child 1960; 35:481–483.
516. Owayed AF, Campbell DM, Wang EE. Underlying causes of recurrent pneumonia in children. Arch Pediatr Adolesc Med 2000; 154:190–194.
517. Raghu G, Yang ST, Spada C, et al
. Sole treatment of acid gastroesophageal reflux in idiopathic pulmonary fibrosis: a case series. Chest 2006; 129:794–800.
518. Tobin RW, Pope CE 2nd, Pellegrini CA, et al
. Increased prevalence of gastroesophageal reflux in patients with idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 1998; 158:1804–1808.
519. Scott RB, O'Loughlin EV, Gall DG. Gastroesophageal reflux in patients with cystic fibrosis. J Pediatr 1985; 106:223–227.
520. Button BM, Roberts S, Kotsimbos TC, et al
. Gastroesophageal reflux (symptomatic and silent): a potentially significant problem in patients with cystic fibrosis before and after lung transplantation. J Heart Lung Transplant 2005; 24:1522–1529.
521. Benden C, Aurora P, Curry J, et al
. High prevalence of gastroesophageal reflux in children after lung transplantation. Pediatr Pulmonol 2005; 40:68–71.
522. Sheikh S, Allen E, Shell R, et al
. Chronic aspiration without gastroesophageal reflux as a cause of chronic respiratory symptoms in neurologically normal infants. Chest 2001; 120:1190–1195.
523. Cucchiara S, Santamaria F, Minella R, et al
. Simultaneous prolonged recordings of proximal and distal intraesophageal pH in children with gastroesophageal reflux disease and respiratory symptoms. Am J Gastroenterol 1995; 90:1791–1796.
524. Knauer-Fischer S, Ratjen F. Lipid-laden macrophages in bronchoalveolar lavage fluid as a marker for pulmonary aspiration. Pediatr Pulmonol 1999; 27:419–422.
525. Ahrens P, Noll C, Kitz R, et al
. Lipid-laden alveolar macrophages (LLAM): a useful marker of silent aspiration in children. Pediatr Pulmonol 1999; 28:83–88.
526. Bauer ML, Lyrene RK. Chronic aspiration in children: evaluation of the lipid-laden macrophage index. Pediatr Pulmonol 1999; 28:94–100.
527. Staugas R, Martin AJ, Binns G, et al
. The significance of fat-filled macrophages in the diagnosis of aspiration associated with gastro-oesophageal reflux. Aust Paediatr J 1985; 21:275–277.
528. Nussbaum E, Maggi JC, Mathis R, et al
. Association of lipid-laden alveolar macrophages and gastroesophageal reflux in children. J Pediatr 1987; 110:190–194.
529. Rosen R, Fritz J, Nurko A, et al
. Lipid-laden macrophage index is not an indicator of gastroesophageal reflux-related respiratory disease in children. Pediatrics 2008; 121:e879–e884.
530. Bohmer CJ, Niezen-de Boer RC, Klinkenberg-Knol EC, et al
. Omeprazole: therapy of choice in intellectually disabled children. Arch Pediatr Adolesc Med 1998; 152:1113–1118.
531. Wilkinson JD, Dudgeon DL, Sondheimer JM. A comparison of medical and surgical treatment of gastroesophageal reflux in severely retarded children. J Pediatr 1981; 99:202–205.
532. Wales PW, Diamond IR, Dutta S, et al
. Fundoplication and gastrostomy versus image-guided gastrojejunal tube for enteral feeding in neurologically impaired children with gastroesophageal reflux. J Pediatr Surg 2002; 37:407–412.
533. Cheung KM, Tse HW, Tse PW, et al
. Nissen fundoplication and gastrostomy in severely neurologically impaired children with gastroesophageal reflux. Hong Kong Med J 2006; 12:282–288.
534. Koufman JA. The otolaryngologic manifestations of gastroesophageal reflux disease (GERD): a clinical investigation of 225 patients using ambulatory 24-hour pH monitoring and an experimental investigation of the role of acid and pepsin in the development of laryngeal injury. Laryngoscope 1991; 101:1–78.
535. Fitzgerald JM, Allen CJ, Craven MA, et al
. Chronic cough and gastroesophageal reflux. CMAJ 1989; 140:520–524.
536. Ing AJ, Ngu MC, Breslin AB. Chronic persistent cough and gastro-oesophageal reflux. Thorax 1991; 46:479–483.
537. Curran AJ, Barry MK, Callanan V, et al
. A prospective study of acid reflux and globus pharyngeus using a modified symptom index. Clin Otolaryngol Allied Sci 1995; 20:552–554.
538. Woo P, Noordzij P, Ross JA. Association of esophageal reflux and globus symptom: comparison of laryngoscopy and 24-hour pH manometry. Otolaryngol Head Neck Surg 1996; 115:502–507.
539. Wilson JA, White A, von Haacke NP, et al
. Gastroesophageal reflux and posterior laryngitis. Ann Otol Rhinol Laryngol 1989; 98:405–410.
540. Shaw GY, Searl JP. Laryngeal manifestations of gastroesophageal reflux before and after treatment with omeprazole. South Med J 1997; 90:1115–1122.
541. Branski RC, Bhattacharyya N, Shapiro J. The reliability of the assessment of endoscopic laryngeal findings associated with laryngopharyngeal reflux disease. Laryngoscope 2002; 112:1019–1024.
542. Hicks DM, Ours TM, Abelson TI, et al
. The prevalence of hypopharynx findings associated with gastroesophageal reflux in normal volunteers. J Voice 2002; 16:564–579.
543. McMurray JS, Gerber M, Stern Y, et al
. Role of laryngoscopy, dual pH probe monitoring, and laryngeal mucosal biopsy in the diagnosis of pharyngoesophageal reflux. Ann Otol Rhinol Laryngol 2001; 110:299–304.
544. Contencin P, Narcy P. Gastropharyngeal reflux in infants and children. A pharyngeal pH monitoring study. Arch Otolaryngol Head Neck Surg 1992; 118:1028–1030.
545. Yellon RF, Coticchia J, Dixit S. Esophageal biopsy for the diagnosis of gastroesophageal reflux-associated otolaryngologic problems in children. Am J Med 2000; 108(Suppl 4a):131S–138S.
546. Gumpert L, Kalach N, Dupont C, et al
. Hoarseness and gastroesophageal reflux in children. J Laryngol Otol 1998; 112:49–54.
547. Halstead LA. Gastroesophageal reflux: a critical factor in pediatric subglottic stenosis. Otolaryngol Head Neck Surg 1999; 120:683–688.
548. Conley SF, Werlin SL, Beste DJ. Proximal pH-metry for diagnosis of upper airway complications of gastroesophageal reflux. J Otolaryngol 1995; 24:295–298.
549. Matthews BL, Little JP, McGuirt WF Jr, et al
. Reflux in infants with laryngomalacia: results of 24-hour double-probe pH monitoring. Otolaryngol Head Neck Surg 1999; 120:860–864.
550. Suskind DL, Zeringue GP 3rd, Kluka EA, et al
. Gastroesophageal reflux and pediatric otolaryngologic disease: the role of antireflux surgery. Arch Otolaryngol Head Neck Surg 2001; 127:511–514.
551. Allen CJ, Anvari M. Does laparoscopic fundoplication provide long-term control of gastroesophageal reflux related cough? Surg Endosc 2004; 18:633–637.
552. Wo JM, Grist WJ, Gussack G, et al
. Empiric trial of high-dose omeprazole in patients with posterior laryngitis: a prospective study. Am J Gastroenterol 1997; 92:2160–2165.
553. Kamel PL, Hanson D, Kahrilas PJ. Omeprazole for the treatment of posterior laryngitis [see comments]. Am J Med 1994; 96:321–326.
554. Hanson DG, Kamel PL, Kahrilas PJ. Outcomes of antireflux therapy for the treatment of chronic laryngitis. Ann Otol Rhinol Laryngol 1995; 104:550–555.
555. Vaezi MF, Richter JE, Stasney CR, et al
. Treatment of chronic posterior laryngitis with esomeprazole. Laryngoscope 2006; 116:254–260.
556. Wo JM, Koopman J, Harrell SP, et al
. Double-blind, placebo-controlled trial with single-dose pantoprazole for laryngopharyngeal reflux. Am J Gastroenterol 2006; 101:1972–1978, quiz 2169.
557. Karkos PD, Wilson JA. Empiric treatment of laryngopharyngeal reflux with proton pump inhibitors: a systematic review. Laryngoscope 2006; 116:144–148.
558. Qadeer MA, Phillips CO, Lopez AR, et al
. Proton pump inhibitor therapy for suspected GERD-related chronic laryngitis: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2006; 101:2646–2654.
559. Williams RB, Szczesniak MM, Maclean JC, et al
. Predictors of outcome in an open label, therapeutic trial of high-dose omeprazole in laryngitis. Am J Gastroenterol 2004; 99:777–785.
560. Corrado G, D'Eufemia P, Pacchiarotti C, et al
. Irritable oesophagus syndrome as cause of chronic cough. Ital J Gastroenterol 1996; 28:526–530.
561. Tasker A, Dettmar PW, Panetti M, et al
. Reflux of gastric juice and glue ear in children. Lancet 2002; 359:493.
562. Weaver EM. Association between gastroesophageal reflux and sinusitis, otitis media, and laryngeal malignancy: a systematic review of the evidence. Am J Med 2003; 115:81S–89S.
563. Bothwell MR, Parsons DS, Talbot A, et al
. Outcome of reflux therapy on pediatric chronic sinusitis. Otolaryngol Head Neck Surg 1999; 121:255–262.
564. Contencin P, Narcy P. Nasopharyngeal pH monitoring in infants and children with chronic rhinopharyngitis. Int J Pediatr Otorhinolaryngol 1991; 22:249–256.
565. El-Serag HB, Gilger M, Kuebeler M, et al
. Extraesophageal associations of gastroesophageal reflux disease in children without neurologic defects. Gastroenterology 2001; 121:1294–1299.
566. Gibson WS Jr, Cochran W. Otalgia in infants and children - a manifestation of gastroesophageal reflux. Int J Pediatr Otorhinolaryngol 1994; 28:213–218.
567. Bartlett DW, Coward PY, Nikkah C, et al
. The prevalence of tooth wear in a cluster sample of adolescent schoolchildren and its relationship with potential explanatory factors. Br Dent J 1998; 184:125–129.
568. O'Sullivan EA, Curzon ME, Roberts GJ, et al
. Gastroesophageal reflux in children and its relationship to erosion of primary and permanent teeth. Eur J Oral Sci 1998; 106:765–769.
569. Cerimagic D, Ivkic G, Bilic E. Neuroanatomical basis of Sandifer's syndrome: a new vagal reflex? Med Hypotheses 2008; 70:957–961.
570. Kinsbourne M. Hiatus Hernia with contortions of the neck. Lancet 1964; 13:1058–1061.